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(57) ABSTRACT 
The invention relates to the identification of new polypeptide 
and protein variants of fibroblast growth factor 21 (FGF21) 
that have improved pharmaceutical properties. Also disclosed 
are methods for treating FGF21-associated disorders, includ 
ing metabolic conditions. 
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METHODS OF TREATING 
FGF21-ASSOCATED DSORDERS 
FIELD OF THE INVENTION 
0001. The present invention relates to new polypeptide of 
fibroblast growth factor 21 (FGF21) that have improved phar 
maceutical properties. Also disclosed are methods for treat 
ing FGF21-associated disorders, such as obesity, type 1 and 
type 2 diabetes mellitus, pancreatitis, dyslipidemia, nonalco 
holic steatohepatitis (NASH), insulin resistance, hyperin 
Sulinemia, glucose intolerance, hyperglycemia, metabolic 
syndrome, and other metabolic disorders, and in reducing the 
mortality and morbidity of critically ill patients. 
BACKGROUND OF THE INVENTION 
0002. The fibroblast growth factor (FGF) family is char 
acterized by 22 genetically distinct, homologous ligands, 
which are grouped into seven subfamilies. According to the 
published literature, the FGF family now consists of at least 
twenty-three members, FGF-1 to FGF-23 (Reuss et al., Cell 
Tissue Res. 313:139-157 (2003). 
0003 FGF-21 was isolated from mouse embryos and is 
closest to FGF-19 and FGF-23. This FGF subfamily regulates 
diverse physiological processes uncommon to classical 
FGFs, namely energy and bile acid homeostasis, glucose and 
lipid metabolism and phosphate as well as vitamin Dhomeo 
stasis. Moreover, unlike classical FGFs, this subfamily acts in 
an endocrine fashion. (Moore, D. D. (2007) Science 316, 
1436-8). Fibroblast growth factor 21 (FGF21) has been 
reported to be preferentially expressed in the liver (Nishimura 
et al., Biochimica et Biophysica Acta, 1492:203-206, (2000); 
patent publication WOO1/36640; and patent publication 
WO01/18172) and described as a treatment for ischemic vas 
cular disease, wound healing, and diseases associated with 
loss of pulmonary, bronchia or alveolar cell function and 
numerous other disorders. 
0004 FGF21 has been identified as a potent metabolic 
regulator. Systemic administration of FGF21 to rodents and 
rhesus monkeys with diet-induced or genetic obesity and 
diabetes exerts strong anti-hyperglycemic and triglyceride 
lowering effects, and reduction of body weight. (Coskun, T, et 
al. (2008) Endocrinology 149:6018-6027; Kharitonenkov, A. 
etal. (2005) Journal of Clinical Investigation 115:1627-1635: 
Kharitonenkov, A. et al. (2007) Endocrinology 148:774-781; 
Xu, J, et al. (2009) Diabetes 58:250-259). FGF21 is a 209 
amino acid polypeptide containing a 28 amino acid leader 
sequence. Human FGF21 has about 79% amino acid identity 
to mouse FGF21 and about 80% amino acid identity to rat 
FGF21. 
0005. Although FGF-21 activates FGF receptors and 
downstream signaling molecules, including FRS2a and ERK, 
direct interaction of FGFRs and FGF-21 has not been 
detected. Furthermore, various non-adipocyte cells do not 
respond to FGF-21, even though they express multiple FGFR 
isoforms. All of these data Suggest that a cofactor must medi 
ate FGF-21 signaling through FGFRs. Recent studies have 
identified f-klotho, which is highly expressed in liver, adipo 
cytes and in pancreas, as a determinant of the cellular 
response to FGF-21 (Kurosu, H. et al. (2007) J Biol Chem 
282, 26687-95). (3-klotho preferentially binds to FGFR1c 
and FGFR4. The B-klotho-FGFR complex, but not FGFR 
alone, binds to FGF-21 in vitro (Kharitonenkov, A. et al. 
(2008) J Cell Physiol 215, 1-7). A similar mechanism has 
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been identified in the FGF-23-klotho-FGFR 
(Urakawa, I. et al. (2006) Nature 444, 770-4). 
0006. The bioactivity of FGF-21 was first identified in a 
mouse 3T3-L1 adipocyte glucose uptake assay (Kharitonen 
kov, A. et al. (2005) J Clin Invest 115, 1627-35). Subse 
quently, FGF-21 was shown to induce insulin-independent 
glucose uptake and GLUT1 expression. FGF-21 has also 
been shown to ameliorate hyperglycemia in a range of dia 
betic rodent models. In addition, transgenic mice over-ex 
pressing FGF-21 were found to be resistant to diet-induced 
metabolic abnormalities, including decreased body weight 
and fat mass, and enhancements in insulin sensitivity (Bad 
man, M. K. et al. (2007) Cell Metab 5, 426-37). Administra 
tion of FGF-21 to diabetic non-human primates caused a 
decline in fasting plasma glucose, triglycerides, insulin and 
glucagon levels, and led to significant improvements in lipo 
protein profiles including a nearly 80% increase in HDL 
cholesterol (Kharitonenkov, A. et al. (2007) Endocrinology 
148,774-81). Importantly, hypoglycemia was not observed at 
any point during this NHP study. Moreover, recent studies 
identified FGF-21 as an important endocrine hormone that 
helps to control adaptation to the fasting state. This provides 
a previously missing link, downstream of PPARC, by which 
the liver communicates with the rest of the body in regulating 
the biology of energy homeostasis. 
0007. The combined observations that FGF-21 regulates 
adipose (lipolysis), liver (fatty acid oxidation and ketogen 
esis), and brain (torpor) establish it as a major endocrine 
regulator of the response to fasting (Kharitonenkov, A. & 
Shanafelt, A. B. (2008) BioDrugs 22, 37–44). However, the 
problem with using FGF-21 directly as a biotherapeutic is 
that its half-life is very short. In mice, the half-life of human 
FGF21 is 0.5 to 1 hours, and in cynomolgus monkeys, the 
half-life is 2 to 3 hours. 
0008. In developing an FGF21 protein for use as a thera 
peutic in the treatment of type 1 and type 2 diabetes mellitus 
and other metabolic conditions, an increase in half-life and 
stability would be desirable. FGF21 proteins having 
enhanced half-life and stability would allow for less frequent 
dosing of patients being administered the protein. Clearly, 
there is a need to develop a stable aqueous protein formula 
tion for the therapeutic protein FGF21. 
0009 FGF21 may be utilized as a multi-use, sterile phar 
maceutical formulation. However, it has been determined that 
preservatives, i.e., m-cresol, have an adverse affect on its 
stability under these conditions. The present invention over 
comes the significant hurdles of physical instabilities with the 
invention of variants of FGF21 that are more stable, less 
Susceptible to proteolysis and enzymatic degradation, and 
less likely to aggregate and form complexes, than wild-type 
FGF21 under pharmaceutical formulation conditions. 
0010 Thus, the variants of FGF21 of the present invention 
provide stable pharmacological protein formulations that are 
useful for the treatment of FGF21-associated disorders, such 
as obesity, type 2 diabetes mellitus, type 1 diabetes mellitus, 
pancreatitis, dyslipidemia, nonalcoholic steatohepatitis 
(NASH), insulin resistance, hyperinsulinemia, glucose intol 
erance, hyperglycemia, metabolic syndrome, hypertension, 
cardiovascular disease, atherosclerosis, peripheral arterial 
disease, stroke, heart failure, coronary heart disease, kidney 
disease, diabetic complications, neuropathy, gastroparesis 
system 
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and other metabolic disorders, and in reducing the mortality 
and morbidity of critically ill patients. 
SUMMARY OF THE INVENTION 
0011. The invention relates to the identification of new 
polypeptide and protein variants of fibroblast growth factor 
21 (FGF21) that have improved pharmaceutical properties, 
e.g., are more stable, less Susceptible to proteolysis and enzy 
matic degradation, and less likely to aggregate and form 
complexes, than wild-type FGF21 under pharmaceutical for 
mulation conditions. Also disclosed are methods for treating 
FGF21-associated disorders, including metabolic conditions. 
0012. The FGF21 protein variants of the present invention 
may be used as a once weekly injectable either alone or in 
combination with oral anti-diabetic agents which will 
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improve the glycemic control, body weight and lipid profile 
of type 1 and type 2 diabetes mellitus patients. In a first aspect, 
the invention provides polypeptide and protein variants of 
Fibroblast Growth Factor 21 (FGF21), which include but are 
not limited to one or more of the sequences listed in Table 1, 
and further described herein. Said FGF21 variants of Table 1 
comprise 4 amino acid N-terminally truncated mature FGF21 
wild-type proteins (i.e., 4 residue N-terminal truncated ver 
sions of the mature FGF21 sequence (SEQID NO:3)) with a 
variety of site-specific internal modifications. The variants of 
Table 1 are numbered relative to the full length FGF21 protein 
sequence (NCBI reference sequence number NP 061986.1); 
for example, the aspartic acid residue in position one of Vari 
ant 1 (SEQ ID NO:5) corresponds to residue number 33 of 
SEQ ID NO:1 (and residue number 5 of mature FGF21 
sequence (SEQID NO:3)). 
TABLE 1. 
List of FGF21 variants, amino acid sequences and amino acid changes 
relative to wild type FGF21 (SEQ ID NO: 1) . 
SEQ 
Variant ID NO: Sequence 
1. 5 DSSPLLOFGG 
IREDGTAGGA 
ILGWKTSRFL 
LWLEDGY 
PAPRGPA 
EPPDWGSSD 
i. 
SSPLLOFGG 
DGTAGGA 
GWKTSRFL 
RELWLEDGY 
PAPRGPA 
NPPDWGSSD 
R E 
SSPLLOFGG 
DGTWGGA 
GWKASRFL 
RELLLENGY 
PASQGPA 
OPPDWGSSD 
R E 
SSPLLOFGG 
DGTWGGA 
LGWOTSRFL 
RELLLENGY 
PASQGPA 
OPPDWGSSD 
R E 
SSPLLOFGG 
DGTWGGA 
GWKASRFL 
RELLLENGY 
PASQGPA 
OPPDWGSSD 
R E 
SSPLLOFGG 
DGTWGGA 
LGWOTSRFL 
RELLLENGY 
RDPASQGPA 
OPPDWGSSD 
R E 
9 11 DSSPLLOFGG 
IREDGTWGGA 
Site-specific modifications 
made relative to 
prior art SEQ ID NO: 1 
(full length FGF21 
protein sequence 
(NCBI reference sequence 
number NP 061986.1) 
QWRORYLYTD DAQETEAHLE Q56E V69A, Q82E R105G, 
ADOSPESLLE LKALKPGVIO L127W, N149H, O184E, 
COGPDGALYG SLHFDPEACS A208T 
NWYOSEAHGL PLHLPGHKSP 
RFLPLPGLPP ALPEPPGILA 
PLSMVGPSOG RSPSYTS 
QWRORYLYTD DAQNTEAHLE Q56N, W69A, Q82N, 
ADQSPESLLN LKALKPGVIQ R105K, L127W, N149Q, 
COKPDGALYG SLHFDPEACS Q184N A208T 
NWYOSEAHGL PLHLPGQKSP 
RFLPLPGLPP ALPEPPGILA 
PLSMVGPSOG RSPSYTS 
QWRORYLYTD DDQQTEAHLE A54D, D74H. T98A, R105K, 
AHOSPESLLO LKALKPGVIQ D13 ON, K15 OR P158S, 
COKPDGALYG SLHFDPEACS R159Q, S195A. G2O2A 
NWYOSEAHGL PLHLPGNRSP 
RFLPLPGLPP ALPEPPGILA 
PLAMWGPSQA RSPSYAS 
QWRORYLYTD DDQQTEAHLE A54D, D74H, KS 7Q, R105K, 
AHOSPESLLO LKALKPGVIQ D13 ON A139T. P158S, 
COKPDGALYG SLHFDPEACS R159Q, S195A. G2O2A 
NVYOSETHGL PLHLPGNKSP 
RFLPLPGLPP ALPEPPGILA 
PLAMWGPSQA RSPSYAS 
OVRORYLYTD DAOETEAHLE Q56E, D74H. T98A, R1O5K, 
AHOSPESLLO LKALKPGVIQ D13 ON, K15 OR P158S, 
COKPDGALYG SLHFDPEACS R159Q, S195A. G2O2A 
NWYOSEAHGL PLHLPGNRSP 
RFLPLPGLPP ALPEPPGILA 
PLAMWGPSQA RSPSYAS 
OVRORYLYTD DAOETEAHLE Q56E, D74H, KS 7Q, R1O5K, 
AHOSPESLLO LKALKPGVIQ D13 ON A139T. P158S, 
COKPDGALYG SLHFDPEACS R159Q, S195A. G2O2A 
NVYOSETHGL PLHLPGNKSP 
RFLPLPGLPP ALPEPPGILA 
PLAMWGPSQA RSPSYAS 
QWRORYLYTD DDQQTEAHLE A54D, D74H. T98A, R105K, 
AHOSPESLLO LKALKPGVIQ D13 ON A139T. P158S, 
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TABLE 1 - continued 
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List of FGF21 variants, amino acid sequences and amino acid changes 
relative to wild type FGF21 (SEQ ID NO: 1) . 
Site-specific modifications 
made relative to 
prior art SEQ ID NO: 1 
(full length FGF21 
protein sequence 
SEQ (NCBI reference sequence 
Variant ID NO: Sequence number NP 061986.1)) 
87 49 DSSPLLOFGG OVRORYLYTD DACOTEAHLE O55C, K84R, K87R, K97R, 
IREDGTWGGA, ADOSPESLLQ LRALRPGVIQ G148C, K15 OR R154K, 
ILGWRTSRFL CORPDGALYG SLHFDPEACS L174P S195A 
FRELLLEDGY NVYOSEAHGL PLHLPCNRSP 
HKDPAPRGPA RFLPLPGLPP APPEPPGILA 
POPPDVGSSD PLAMVGPSQG RSPSYAS 
0013. Other embodiments are drawn to polynucleotides 0017. In some embodiments, the fusion heterologous 
encoding the polypeptide and protein variants of the inven 
tion, a vector containing said polynucleotides and a host cell 
carrying said vector. 
0014 Provided herein are methods used to generate said 
polypeptides and protein variants, wherein Such methods 
involve modification of the wild-type FGF21 protein, via e.g., 
truncations of the wild-type FGF21 protein, and the site 
specific incorporation of amino acids at positions of interest 
within the wild-type FGF21 protein. Said modifications 
enhance the biological properties of the variants of the inven 
tion relative to the wild-type FGF21 protein, as well as, in 
Some cases, serving as points of attachment for, e.g., labels 
and protein half-life extension agents, and for purposes of 
affixing said variants to the Surface of a solid Support. Related 
embodiments of the invention are methods of produce cells 
capable of producing said polypeptide and protein variants, 
and of producing vectors containing DNA encoding said vari 
antS. 
0015. In various embodiments, the polypeptide and pro 
tein variants disclosed herein can comprise (a) an amino 
terminal truncation of no more than 8 amino acid residues, 
wherein the polypeptide is capable of lowering blood glucose 
in a mammal; (b) a carboxyl-terminal truncation of no more 
than 12 amino acid residues, wherein the polypeptide is 
capable of lowering blood glucose in a mammal; or (c) an 
amino-terminal truncation of no more than 8 amino acid 
residues and a carboxyl-terminal truncation of no more than 
12 amino acid residues, wherein the polypeptide is capable of 
lowering blood glucose in a mammal. 
0016. In some embodiments, the polypeptide and protein 
variants disclosed herein can be covalently linked to one or 
more polymers, such as polyethylene glycol (PEG) or poly 
sialic acid, whether at the position of site-specific amino acid 
modifications made relative to the wild-type FGF21, or at the 
position of amino acids commonly shared with the wild-type 
FGF21. In other embodiments, the polypeptides of the inven 
tion can be fused to a heterologous amino acid sequence, 
optionally via a linker, Such as GS or 
GGGGSGGGGSGGGGS (SEQID NO:4). The heterologous 
amino acid sequence can be an IgG constant domain or frag 
ment thereof (e.g., the Fc region), Human Serum Albumin 
(HSA), or albumin-binding polypeptides. Such fusion 
polypeptides disclosed herein can also form multimers. 
amino acid sequence (e.g., HSA, Fc, etc.) is fused to the 
amino-terminal of the protein variants of the invention. In 
other embodiments, the fusion heterologous amino acid 
sequence (e.g., HSA, Fc, etc.) is fused to the carboxyl-termi 
nal of the protein variants of the invention. 
0018 Yet another embodiment is drawn to methods of 
treating a patient exhibiting one or more FGF21-associated 
disorders, such as obesity, type 2 diabetes mellitus, type 1 
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic 
steatohepatitis (NASH), insulin resistance, hyperinsuline 
mia, glucose intolerance, hyperglycemia, metabolic Syn 
drome, hypertension, cardiovascular disease, atherosclerosis, 
peripheral arterial disease, stroke, heart failure, coronary 
heart disease, kidney disease, diabetic complications, neur 
opathy, gastroparesis and other metabolic disorders, compris 
ing administering to said patient in need of Such treatment a 
therapeutically effective amount of one or more human 
FGF21 polypeptide and protein variants of the invention or a 
pharmaceutical composition thereof. 
0019. The invention also provides pharmaceutical compo 
sitions comprising the polypeptide and protein variants dis 
closed herein and a pharmaceutically acceptable formulation 
agent. Such pharmaceutical compositions can be used in a 
method for treating a metabolic disorder, and the method 
comprises administering to a human patient in need thereof a 
pharmaceutical composition of the invention. Non-limiting 
examples of metabolic disorders that can be treated include 
type 1 and type 2 diabetes mellitus and obesity. 
0020. These and other aspects of the invention will be 
elucidated in the following detailed description of the inven 
tion. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0021 FIG. 1 is a graphical representation showing a drop 
in liver triglyceride levels following treatment of ob/ob mice 
for 12 days with PEGylated wildtype FGF21 and the FGF21 
variants of the invention. Liver samples (<50 mg) were 
homogenized in isopropanol: butylated hydroxytoluene 
(BHT or 2,6-di-tert-butyl-4-methylphenol) at a ratio of 1000: 
5, using Qiagentissue lyser (with one 5-mm bead). Following 
homogenization, the samples were gently shaken for 45 min 
at room temperature and then spun down at 6000 rpm for 10 
US 2012/0129766 A1 
min at 4°C. The supernatants were collected and assayed for 
triglyceride content using the Wako triglyceride assay kit. 
0022 FIG. 2 is a graphical representation showing plasma 
exposures of FGF21-WT-R154c-PEG and FGF21-V76 
154C-PEG in ob?ob mice treated for 12 days. FGF21-WT 
R154C-PEG and FGF21-V76-154C-PEG were given subcu 
taneously on days 1, 4, 8 and 11 after Oh time point. 
0023 FIGS. 3A and 3B show ob?ob mouse plasma stabil 
ity of wild type FGF21 (Panel A) and FGF21-V76-154C 
PEG (Panel B). The average plasma contribution to the pERK 
activity (“background activity”) is 28% (range 12-49%) for 
the wildtype FGF21 samples and 58% (range 46–75%) for the 
FGF21-V76-154C-PEG samples. 
DETAILED DESCRIPTION OF THE INVENTION 
0024. A significant challenge in the development of pro 
tein pharmaceuticals, such as FGF21, including the FGF21 
protein variants of the present invention, is to cope with their 
physical and chemical instabilities. The compositional Vari 
ety and characteristics of proteins define specific behaviors 
Such as folding, conformational stability, and unfolding/de 
naturation. Such characteristics must be addressed to stabi 
lize proteins when developing pharmaceutical formulation 
conditions utilizing aqueous protein solutions (Wang, W., Int. 
Met Asp 
Wall Lieu 
Asp Ser 
Lieu. Tyr 
SO 
Glu 
65 
Asp 
Lieu. Glin 
Thir 
Ser Luell 
Glu Asp 
13 O 
His Lieu. 
145 
Pro Ala 
Pro Pro 
Luell Pro 
Ser 
209 
Ser 
Ala 
Ser 
35 
Thir 
Gly 
Luell 
Ser 
His 
115 
Gly 
Pro 
Arg 
Gly 
Ser 
195 
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J. of Pharmaceutics, 18, (1999)). A desired effect of stabiliz 
ing therapeutic proteins of interest, e.g., the FGF21 protein 
variants of the present invention, is increasing resistance to 
proteolysis and enzymatic degradation, thereby improving 
protein stability and reducing protein aggregation. 
0025 Specifically, in pharmaceutical protein develop 
ment, anti-microbial preservative agents such as phenol, 
m-cresol, methylparaben, resorcinol, and benzyl alcohol are 
necessary in parenteral pharmaceutical formulations that are 
intended to be a sterile, multi-use formulation. Unfortunately, 
these compounds often adversely affect the stability of the 
protein product, triggering association and aggregation, in 
particular (Maa et al., Int. J. of Pharmaceutics 140:155-168 
(1996); Lam et al., Pharm. Res. 14(6):725-729 (1997)). 
0026. The FGF21 polypeptide and protein variants of the 
present invention represent modified versions of the full 
length, wild-type FGF21 polypeptide, as known in the art. 
FGF21 wild-type sequence will serve as a reference sequence 
(SEQID NO:1), for instance, when comparisons between the 
FGF21 wild-type sequence and the protein variants are nec 
essary. The FGF21 wild-type sequence has NCBI reference 
sequence number NP 061986.1, and can be found in such 
issued patents as, e.g., U.S. Pat. No. 6,716,626B1, assigned to 
Chiron Corporation. 
Glu Thir Glu Wall 
15 
His Ser Lell Ser Asp Gly Phe Gly Trp 
Ala 
25 
Glin Ala Pro Ile Pro Gly Lieu Lleu Lieu. His Gly 
Glin Phe 
4 O 
Pro Luell Lell Gly Gly Glin Val Arg Glin 
45 
Arg Tyr 
Ala Glin 
55 
Glin Thr Glu Ala His Lieu. Glu Ile 
6 O 
Asp Asp Arg 
Thir Wall Ala Ala Glin Glu Luell Gly Ser Pro Ser 
70 
Gly Asp 
Ala 
85 
Wall 
90 
Lieu Lys Pro Gly Ile Glin Lieu. Gly Val 
95 
Arg Phe Lieu. Glin Pro Cys Arg 
105 
Asp Gly Lel 
11 O 
Tyr Gly 
Phe Glu Ala 
12 O 
Asp Pro Ser Phe Cell Lieu. Luell 
Wall Glin Glu Ala His Pro Leu 
14 O 
Asn Tyr Ser 
135 
Lel 
Gly Asn Lys Ser Pro His Pro 
150 
Arg Asp 
155 
Arg Gly 
160 
Phe Pro Glu 
17s 
Leul Pro Pro 
17O 
Leul Pro Leu Pro 
1.65 
Gly Lel 
Ile 
18O 
Lieu Ala Glin Wall Ser Ser 
19 O 
Pro Pro 
185 
Pro Asp Asp 
Met Glin Pro Ser Ala Ser Ser Val Gly Pro Gly Arg Tyr 
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0027. The corresponding cDNA sequence coding for the 
full-length FGF21 polypeptide (NCBI reference sequence 
number NM 019113.2) is shown below (SEQ ID NO:2) 
atggacticgg acgaga.ccgg gttctgagcac toaggactgt gggtttctgt gctggctggit 
61 cittctgctgg gaggctgcca ggcacacc cc atcc ct gact coagtic ct ct c ctdcaattic 
121 gggggg caag to cqgcagcg gtacct ctac acagatgatg cccagoagac agaag.cccac 
181 ctggagat.ca gggaggatgg gacggtgggg ggcgctgctg accagagc cc caaagtic to 
241 ctgcagctga aagccttgaa gCC9ggagtt attcaaatct togagt caa gacat coagg 
301 tt Cotgtgcc agcggccaga tiggggc cctg. tatggat.cgc. tcc actittga CCCtgaggcc 
361 to agcttico gggagctgct tcttgaggac ggatacaatgtttaccagtic Caag.cccac 
421 ggcct ccc.gc tigcacctgcc agggaacaag ticcic cacacc gggaccctgc accc.cgagga 
481 cc agct cqct tcct gccact accaggcc tig ccc.ccc.gcac toccggagcc acccggaatc 
541 ctggcc cc cc agc.ccc.ccga tigtgggct co toggaccctic taggatggit gggacct tcc 
601 Cagggc.cgala gCCC cagota cqct tcctga 
0028. The mature FGF21 sequence lacks a leader post-translational modifications understood by those with 
sequence and may also include other modifications of a skill in the art. A representative example of a mature FGF21 
polypeptide Such as proteolytic processing of the amino ter- sequence has the following sequence (SEQID NO:3, which 
minus (with or without a leader sequence) and/or the carboxyl represents amino acid positions 29-209 of full length FGF21 
terminus, cleavage of a smaller polypeptide from a larger protein sequence (NCBI reference sequence number 
precursor, N-linked and/or O-linked glycosylation, and other NP 061986.1)): 
His Pro Ile Pro Asp Ser Ser Pro Leu Lleu Glin Phe Gly Gly Glin Val 
Arg Glin Arg Tyr Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His 
2O 25 3 O 
Lieu. Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser 
35 4 O 45 
Pro Glu Ser Lieu. Lieu Gln Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin 
SO 55 60 
Ile Lieu. Gly Val Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly 
65 70 7s 8O 
Ala Lieu. Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg 
85 90 95 
Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His 
1OO 105 11 O 
Gly Lieu Pro Lieu. His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro 
115 12 O 125 
Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Lieu Pro Pro 
13 O 135 14 O 
Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val 
145 150 155 160 
Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser 
1.65 17O 17s 
Pro Ser Tyr Ala Ser 
18O 
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0029. The corresponding cDNA sequence coding for the 
mature FGF21 polypeptide (SEQ ID NO:3) is shown below 
(SEQ ID NO:47): 
caccc.cat co citgact coag to ct ct cotg Caatt.cgggg 
61 ct ct acacag atgatgcc.ca gCagacagaa gcc.cacctgg 
121 gtgggggg.cg Ctgctgacca gagcc.ccgaa agtict cct gc 
181 ggagittatto: aaatcttggg agt caagaca to Caggttcc 
24 O gocctg tatg gatcgcticca ctittgacc ct gaggcCtgca 
3O1 gaggacggat acaatgttta CC agtc.cgaa gcc.cacggcc 
360 aacaagtic cc cacaccggga ccct gcaccc cgaggaccag 
421 ggcctgcc cc cc.gc actic cc ggagccaccc ggaatcCtgg 
48 accctctgag ggct cotcgg catggtggga cct tcc cagg 
541 to ctga 
0030. One skilled in the art of expression of proteins will 
recognize that methionine or methionine-arginine sequence 
can be introduced at the N-terminus of any of the FGF21 
protein variants, for expression in E. coli, and are contem 
plated within the context of this invention. 
0031. The terms “FGF21 protein variant,”“human FGF21 
variant.” “FGF21 polypeptide or protein variant.” “variant.” 
“FGF21 mutant, or any like terms, are defined as comprising 
human FGF21 in which a naturally occurring (i.e., wild-type) 
FGF21 amino acid sequence has been modified, e.g., in which 
at least one amino acid of the wild-type protein has been 
substituted by anotheramino acid, and/or removed. Addition 
ally, the variants may include N- and/or C-terminal trunca 
tions relative to the wild-type FGF21 protein. Generally 
speaking, a variant possesses some modified property, struc 
tural or functional, of the wild-type protein. For example, the 
variant may have enhanced or improved physical stability in 
concentrated Solutions (e.g., less hydrophobic mediated 
aggregation), enhanced or improved plasma stability when 
incubated with blood plasma or enhanced or improved bio 
activity while maintaining a favorable bioactivity profile. 
0032. Acceptable amino acid substitutions and modifica 
tions which constitute differences between the FGF21 
polypeptide and protein variants of the invention and wild 
type FGF21 include, but are not limited to, one or more amino 
acid Substitutions, including Substitutions with non-naturally 
occurring amino acid analogs, and truncations. Thus, FGF21 
protein variants include, but are not limited to, site-directed 
FGF21 mutants, truncated FGF21 polypeptides, proteolysis 
resistant FGF21 mutants, aggregation-reducing FGF21 
mutants, FGF21 combination mutants, and FGF21 fusion 
proteins, as described herein. 
0033. The variant may possess increased compatibility 
with pharmaceutical preservatives (e.g., m-cresol, phenol, 
benzyl alcohol), thus enabling the preparation of a preserved 
pharmaceutical formulation that maintains the physiochemi 
cal properties and biological activity of the protein during 
storage. Accordingly, variants with enhanced pharmaceutical 
stability relative to wild-type FGF21, have improved physical 
stability in concentrated Solutions under both physiological 
and preserved pharmaceutical formulation conditions, while 
maintaining biological potency. By way of non-limiting 
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gccaagtc.cg 
agat caggga 
agctgaaagc 
tgtgc.cagcg 
gct tcc.ggga 
tcc.cgctgca 
citc.gct tcct 
cc.ccc.ca.gc.c 
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gcagogg tac 
ggatgggacg 
Cttgaagc.cg 
gcc agatggg 
gctgcttctt 
CctgcCaggg 
gcc actacca 
CCC catgtg 
cagctacgct 
example, the variants of the invention may be more resistant 
to proteolysis and enzymatic degradation; may have 
improved stability; and may be less likely to aggregate, than 
their wild-type counterparts. As used herein, these terms are 
not mutually exclusive or limiting, it being entirely possible 
that a given variant has one or more modified properties of the 
wild-type protein. 
0034. The invention also encompasses a nucleic acid mol 
ecule encoding an FGF21 polypeptide or protein variant, or 
variant, comprising an amino acid sequence that is at least 
about 95% (alternately 96%, alternately 97%, alternately 
98%, alternately 99%) identical to the amino acid sequence of 
SEQ ID NO:3, but wherein specific residues conferring a 
desirable property to the FGF21 protein variant, e.g., pro 
teolysis-resistance, increased half life or aggregation-reduc 
ing properties and combinations thereofhave not been further 
modified. In other words, with the exception of residues in the 
FGF21 mutant sequence that have been modified in order to 
confer proteolysis-resistance, aggregation-reducing, or other 
properties, about 5% (alternately 4%, alternately 3%, alter 
nately 2%, alternately 1%) of all other amino acid residues in 
the FGF21 mutant sequence can be modified. Such FGF21 
mutants possess at least one activity of the wild-type FGF21 
polypeptide. 
0035. The invention also encompasses a nucleic acid mol 
ecule comprising a nucleotide sequence that is at least about 
95% (alternately 96%, alternately 97%, alternately 98%, 
alternately 99%) identical to the nucleotide sequence of SEQ 
ID NO:47, but wherein the nucleotides encoding amino acid 
residues conferring the encoded FGF21 protein variant's pro 
teolysis-resistance, aggregation-reducing or other properties 
have not been further modified. In other words, with the 
exception of nucleotides that encode residues in the FGF21 
mutant sequence that have been modified in order to confer 
proteolysis-resistance, aggregation-reducing, or other prop 
erties, about 5% (alternately 4%, alternately 3%, alternately 
2%, alternately 1%) of all other nucleotides in the FGF21 
mutant sequence can be modified. Such nucleic acid mol 
ecules encode FGF21 mutant polypeptides possessing at least 
one activity of the wild-type FGF21 polypeptide. 
0036 Provided herein are methods used to generate the 
FGF21 polypeptides and protein variants of the invention, 
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wherein such methods involve site-specific modification of 
the wild-type FGF21 protein, via e.g., truncations of the wild 
type FGF21 protein, and the site-specific incorporation of 
amino acids at positions of interest within the wild-type 
FGF21 protein. Said modifications enhance the biological 
properties of the variants of the invention relative to the wild 
type FGF21 protein, as well as, in some cases, serving as 
points of attachment for, e.g., labels and protein half-life 
extension agents, and for purposes of affixing said variants to 
the surface of a solid support. Related embodiments of the 
invention are methods of producing cells capable of produc 
ing said polypeptide and protein variants, and of producing 
vectors containing DNA encoding said variants. 
0037. In certain embodiments, such site-specific modifi 
cations are used to attach poly(ethylene glycol)(PEG) to pro 
teins, polypeptides, and/or peptides. In other embodiments, 
such site-specific modifications are used to attach PEG-cho 
lesterol conjugates (including micelles and liposomes) to pro 
teins, polypeptides, and/or peptides. In other embodiments, 
Such site-specific modifications are used to attach Sugars (gly 
cosylate) to proteins, polypeptides, and/or peptides. 
0038. In other embodiments, such site-specific modifica 
tions are used as means of attachment for the production of 
FGF21 wild-type and/or variant multimers, e.g., dimers (ho 
modimers or heterodimers) or trimers. These multimeric 
FGF21 molecules may additionally have groups such as PEG, 
Sugars, and/or PEG-cholesterol conjugates attached or be 
fused either amino-terminally or carboxy-terminally to other 
proteins such as Fc, HSA etc. 
0039. In other embodiments, such site-specific modifica 
tions are used to produce proteins, polypeptides and/or pep 
tides wherein the position of the site-specifically incorporated 
pyrrolysine or pyrrolysine analogue allows for controlled 
orientation and attachment of Such proteins, polypeptides 
and/or peptides onto a Surface of a solid Support or to have 
groups such as PEG, Sugars and/or PEG-cholesterol conju 
gates attached. 
0040. In other embodiments, such site-specific modifica 
tions are used to site-specifically cross-link proteins, 
polypeptides and/or peptides thereby forming hetero-oligo 
mers including, but not limited to, heterodimers and heterot 
rimers. In other embodiments, such site-specific modifica 
tions are used to site-specifically cross-link proteins, 
polypeptides and/or peptides thereby forming protein-protein 
conjugates, protein-polypeptide conjugates, protein-peptide 
conjugates, polypeptide-polypeptide conjugates, polypep 
tide-peptide conjugates or peptide-peptide conjugates. 
DEFINITIONS 
0041 Various definitions are used throughout this docu 
ment. Most words have the meaning that would be attributed 
to those words by one skilled in the art. Words specifically 
defined either below or elsewhere in this document have the 
meaning provided in the context of the present invention as a 
whole and as are typically understood by those skilled in the 
art. 
0042. As used herein, the term “FGF21 refers to a mem 
ber of the fibroblast growth factor (FGF) protein family. An 
amino acid sequence of FGF21 (GenBank Accession No. 
NP 061986.1) is set forth as SEQID NO:1, the correspond 
ing polynucleotide sequence of which is set forth as SEQID 
NO:2 (NCBI reference sequence number NM 019113.2). 
0043. As used herein, the term “FGF21 receptor” refers to 
a receptor for FGF21 (Kharitonenkov, A. et al. (2008) Journal 
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of Cellular Physiology 215:1-7: Kurosu, H, et al. (2007).JBC 
282:26687-26695; Ogawa, Y, et al. (2007) PNAS 104:7432 
7437). 
0044) The term “FGF21 polypeptide” refers to a naturally 
occurring polypeptide expressed in humans. For purposes of 
this disclosure, the term “FGF21 polypeptide' can be used 
interchangeably to refer to any full-length FGF21 polypep 
tide, e.g., SEQ ID NO:1, which consists of 209 amino acid 
residues and which is encoded by the nucleotide sequence of 
SEQ ID NO:2; any mature form of the polypeptide, which 
consists of 181 amino acid residues, and in which the 28 
amino acid residues at the amino-terminal end of the full 
length FGF21 polypeptide (i.e., which constitute the signal 
peptide) have been removed, and variants thereof. 
0045. The term "isolated nucleic acid molecule” refers to 
a nucleic acid molecule of the present invention that (1) has 
been separated from at least about 50 percent of proteins, 
lipids, carbohydrates, or other materials with which it is natu 
rally found when total nucleic acid is isolated from the source 
cells, (2) is not linked to all or a portion of a polynucleotide to 
which the "isolated nucleic acid molecule' is linked in nature, 
(3) is operably linked to a polynucleotide which it is not 
linked to in nature, or (4) does not occur in nature as part of a 
larger polynucleotide sequence. Preferably, the isolated 
nucleic acid molecule of the present invention is substantially 
free from any other contaminating nucleic acid molecules or 
other contaminants that are found in its natural environment 
that would interfere with its use in polypeptide production or 
its therapeutic, diagnostic, prophylactic or research use. 
0046. The term “vector” is used to refer to any molecule 
(e.g., nucleic acid, plasmid, or virus) used to transfer coding 
information to a host cell. 
0047. The term “expression vector” refers to a vector that 
is Suitable for transformation of a host cell and contains 
nucleic acid sequences that direct and/or control the expres 
sion of inserted heterologous nucleic acid sequences. Expres 
sion includes, but is not limited to, processes such as tran 
Scription, translation, and RNA splicing, if introns are 
present. 
0048. The term “operably linked' is used herein to refer to 
an arrangement of flanking sequences wherein the flanking 
sequences so described are configured or assembled so as to 
perform their usual function. Thus, a flanking sequence oper 
ably linked to a coding sequence may be capable of effecting 
the replication, transcription and/or translation of the coding 
sequence. For example, a coding sequence is operably linked 
to a promoter when the promoter is capable of directing 
transcription of that coding sequence. A flanking sequence 
need not be contiguous with the coding sequence, so long as 
it functions correctly. Thus, for example, intervening untrans 
lated yet transcribed sequences can be present between a 
promoter sequence and the coding sequence and the promoter 
sequence can still be considered “operably linked to the 
coding sequence. 
0049. The term “host cell is used to refer to a cell which 
has been transformed, or is capable of being transformed with 
a nucleic acid sequence and then of expressing a selected gene 
of interest. The term includes the progeny of the parent cell, 
whether or not the progeny is identical in morphology or in 
genetic make-up to the original parent, so long as the selected 
gene is present. 
0050. The term “amino acid,” as used herein, refers to 
naturally occurring amino acids, unnatural amino acids, 
amino acid analogues and amino acid mimetics that function 
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in a manner similar to the naturally occurring amino acids, all 
in their D and L stereoisomers if their structure allows such 
stereoisomeric forms. Amino acids are referred to herein by 
either their name, their commonly known three letter symbols 
or by the one-letter symbols recommended by the IUPAC 
IUB Biochemical Nomenclature Commission. 
0051. The term “naturally occurring” when used in con 
nection with biological materials such as nucleic acid mol 
ecules, polypeptides, host cells, and the like, refers to mate 
rials which are found in nature and are not manipulated by 
man. Similarly, “non-naturally occurring as used herein 
refers to a material that is not found in nature or that has been 
structurally modified or synthesized by man. When used in 
connection with nucleotides, the term “naturally occurring 
refers to the bases adenine (A), cytosine (C), guanine (G), 
thymine (T), and uracil (U). When used in connection with 
amino acids, the term “naturally occurring refers to the 20 
conventional amino acids (i.e., alanine (A), cysteine (C), 
aspartic acid (D), glutamic acid (E), phenylalanine (F), gly 
cine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), 
methionine (M), asparagine (N), proline (P), glutamine (Q). 
arginine (R), serine (S), threonine (T), Valine (V), tryptophan 
(W), and tyrosine (Y)), as well as selenocysteine, pyrrolysine 
(PYL), and pyrroline-carboxy-lysine (PCL). 
0052 Pyrrolysine (PYL) is an amino acid naturally found 
within methylamine methyltransferases of methanogenic 
archaea of the family Methanosarcina. Pyrrolysine is alysine 
analogue co-translationally incorporated at in-frame UAG 
codons in the respective mRNA, and it is considered the 22nd 
natural amino acid. 
0053 As described at least in PCT patent publication 
WO2010/48582 (applicant IRM, LLC), attempts to biosyn 
thesize pyrrolysine (PYL) in E. coli resulted in the formation 
of a “demethylated pyrrolysine” referred to herein as pyrro 
line-carboxy-lysine, or PCL. “PCL as used herein, refers to 
either PCL-A or PCL-B. 
0054 The terms “non-natural amino acid' and “unnatural 
amino acid, as used herein, are interchangeably intended to 
representamino acid structures that cannot be generated bio 
synthetically in any organism using unmodified or modified 
genes from any organism, whether the same or different. The 
terms refer to an amino acid residue that is not present in the 
naturally occurring (wild-type) FGF21 protein sequence or 
the sequences of the FGF21 variants of the present invention. 
These include, but are not limited to, modified amino acids 
and/or amino acid analogues that are not one of the 20 natu 
rally occurring amino acids, selenocysteine, pyrrolysine 
(PYL), or pyrroline-carboxy-lysine (PCL). Such non-natural 
amino acid residues can be introduced by substitution of 
naturally occurring amino acids, and/or by insertion of non 
natural amino acids into the naturally occurring (wild-type) 
FGF21 protein sequence or the sequences of the FGF21 vari 
ants of the invention. The non-natural amino acid residue also 
can be incorporated Such that a desired functionality is 
imparted to the FGF21 molecule, for example, the ability to 
link a functional moiety (e.g., PEG). 
0055. In addition, it is understood that such “unnatural 
amino acids’ require a modified tRNA and a modified tRNA 
synthetase (RS) for incorporation into a protein. These 
“selected orthogonal tRNA/RS pairs are generated by a 
selection process as developed by Schultz et al. or by random 
or targeted mutation. As way of example, pyrroline-carboxy 
lysine is a “natural amino acid as it is generated biosyntheti 
cally by genes transferred from one organism into the host 
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cells and as it is incorporated into proteins by using natural 
tRNA and tRNA synthetase genes, while p-aminophenylala 
nine (See, Generation of a bacterium with a 21 amino acid 
genetic code, Mehl RA. Anderson J C, Santoro SW, Wang L, 
Martin A B, King DS, Horn DM, Schultz, P G. JAm Chem. 
Soc. 2003 Jan. 29; 125(4):935-9) is an “unnatural amino 
acid because, although generated biosynthetically, it is 
incorporated into proteins by a “selected orthogonal tRNA/ 
tRNA synthetase pair. 
0056 Modified encoded amino acids include, but are not 
limited to, hydroxyproline, Y-carboxyglutamate, O-phospho 
serine, aZetidinecarboxylic acid, 2-aminoadipic acid, 3-ami 
noadipic acid, beta-alanine, aminopropionic acid, 2-ami 
nobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 
2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-ami 
noisobutyric acid, 2-aminopimelic acid, tertiary-butylgly 
cine, 2,4-diaminoisobutyric acid, desmosine, 2,2'-diami 
nopimelic acid, 2,3-diaminoproprionic acid, N-ethylglycine, 
N-methylglycine, N-ethylasparagine, homoproline, 
hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hy 
droxyproline, isodesmosine, allo-isoleucine, N-methylala 
nine, N-methylglycine, N-methylisoleucine, N-methylpen 
tylglycine, N-methylvaline, naphthalanine, norvaline, 
norleucine, ornithine, pentylglycine, pipecolic acid and thio 
proline. The term “amino acid also includes naturally occur 
ring amino acids that are metabolites in certain organisms but 
are not encoded by the genetic code for incorporation into 
proteins. Such amino acids include, but are not limited to, 
ornithine, D-ornithine, and D-arginine. 
0057 The term “amino acid analogue,” as used herein, 
refers to compounds that have the same basic chemical struc 
ture as a naturally occurring amino acid, by way of example 
only, an O-carbon that is bound to a hydrogen, a carboxyl 
group, an amino group, and an R group Amino acid analogues 
include the natural and unnatural amino acids which are 
chemically blocked, reversibly or irreversibly, or their C-ter 
minal carboxy group, their N-terminal amino group and/or 
their side-chain functional groups are chemically modified. 
Such analogues include, but are not limited to, methionine 
Sulfoxide, methionine Sulfone, S-(carboxymethyl)-cysteine, 
5-(carboxymethyl)-cysteine sulfoxide, S-(carboxymethyl)- 
cysteine Sulfone, aspartic acid-(beta-methyl ester), N-ethylg 
lycine, alanine carboxamide, homoserine, norleucine, and 
methionine methyl Sulfonium. 
0058. The term “amino acid mimetics,” as used herein, 
refers to chemical compounds that have a structure that is 
different from the general chemical structure of an amino 
acid, but functions in a manner similar to a naturally occurring 
amino acid. 
0059. The term “biologically active FGF21 variant” refers 
to any FGF21 polypeptide variant described herein that pos 
sesses an activity of the wild-type FGF21 polypeptide, such 
as the ability to lower blood glucose, insulin, triglyceride, or 
cholesterol; reduce body weight; and to improve glucose 
tolerance, energy expenditure, or insulin sensitivity, regard 
less of the type or number of modifications that have been 
introduced into the FGF21 polypeptide variant. FGF21 
polypeptide variants possessing a somewhat decreased level 
of FGF21 activity relative to the wild-type FGF21 polypep 
tide can nonetheless be considered to be biologically active 
FGF21 polypeptide variants. 
0060. The terms “effective amount” and “therapeutically 
effective amount’ each refer to the amount of an FGF21 
protein variant used to support an observable level of one or 
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more biological activities of the wild-type FGF21 polypep 
tide. Such as the ability to lower blood glucose, insulin, trig 
lyceride or cholesterol levels; reduce liver triglyceride or lipid 
levels; reduce body weight; or improve glucose tolerance, 
energy expenditure, or insulin sensitivity. For example, a 
“therapeutically-effective amount administered to a patient 
exhibiting, suffering, or prone to suffer from FGF21-associ 
ated disorders (such as type 1 or type 2 diabetes mellitus, 
obesity, or metabolic syndrome), is such an amount which 
induces, ameliorates or otherwise causes an improvement in 
the pathological symptoms, disease progression, physiologi 
cal conditions associated with or resistance to Succumbing to 
the afore mentioned disorders. For the purposes of the present 
invention a “subject' or “patient' is preferably a human, but 
can also be an animal, more specifically, a companion animal 
(e.g., dogs, cats, and the like), farm animals (e.g., cows, 
sheep, pigs, horses, and the like) and laboratory animals (e.g., 
rats, mice, guinea pigs, and the like). 
0061 The term “pharmaceutically acceptable carrier' or 
“physiologically acceptable carrier as used herein refers to 
one or more formulation materials Suitable for accomplishing 
or enhancing the delivery of an FGF21 protein variant. 
0062. The term “antigen” refers to a molecule or a portion 
of a molecule that is capable of being bound by an antibody, 
and additionally that is capable of being used in an animal to 
produce antibodies that are capable of binding to an epitope of 
that antigen. An antigen may have one or more epitopes. 
0063. The term “native Fc refers to molecule or sequence 
comprising the sequence of a non-antigen-binding fragment 
resulting from digestion of whole antibody or produced by 
other means, whether in monomeric or multimeric form, and 
can contain the hinge region. The original immunoglobulin 
Source of the native Fc is preferably of human origin and can 
be any of the immunoglobulins, although IgG1 and IgG2 are 
preferred. Native Fc molecules are made up of monomeric 
polypeptides that can be linked into dimeric or multimeric 
forms by covalent (i.e., disulfide bonds) and non-covalent 
association. The number of intermolecular disulfide bonds 
between monomeric Subunits of native Fc molecules ranges 
from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or 
Subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2). One 
example of a native Fc is a disulfide-bonded dimer resulting 
from papain digestion of an IgG (see Ellison et al., 1982, 
Nucleic Acids Res. 10:4071-9). The term “native Fc” as used 
herein is generic to the monomeric, dimeric, and multimeric 
forms. The term “Fc variant” refers to a molecule or sequence 
that is modified from a native Fc but still comprises a binding 
site for the salvage receptor, FcRn (neonatal Fc receptor). 
International Publication Nos. WO 97/34631 and WO 
96/32478 describe exemplary Fc variants, as well as interac 
tion with the Salvage receptor, and are hereby incorporated by 
reference. Thus, the term “Fc variant can comprise a mol 
ecule or sequence that is humanized from a non-human native 
Fc. Furthermore, a native Fc comprises regions that can be 
removed because they provide structural features or biologi 
cal activity that are not required for the fusion molecules of 
the FGF21 mutants of the present invention. Thus, the term 
“Fc variant comprises a molecule or sequence that lacks one 
or more native Fc sites or residues, or in which one or more Fc 
sites or residues has be modified, that affector are involved in: 
(1) disulfide bond formation, (2) incompatibility with a 
selected host cell, (3) N-terminal heterogeneity upon expres 
sion in a selected host cell, (4) glycosylation, (5) interaction 
with complement, (6) binding to an Fc receptor other than a 
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salvage receptor, or (7) antibody-dependent cellular cytotox 
icity (ADCC). Fc variants are described in further detail here 
inafter. 
0064. The term “Fc domain encompasses native Fc and 
Fc variants and sequences as defined above. As with Fc vari 
ants and native Fc molecules, the term "Fc domain includes 
molecules in monomeric or multimeric form, whether 
digested from whole antibody or produced by other means. In 
Some embodiments of the present invention, an Fc domain 
can be fused to FGF21 or a FGF21 mutant (including a 
truncated form of FGF21 or a FGF21 mutant) via, for 
example, a covalent bond between the Fc domain and the 
FGF21 sequence. Such fusion proteins can form multimers 
via the association of the Fc domains and both these fusion 
proteins and their multimers are an aspect of the present 
invention. 
0065. The term “polyethylene glycol” or “PEG” refers to 
a polyalkylene glycol compound or a derivative thereof, with 
or without coupling agents or derviatization with coupling or 
activating moieties. 
0066. The term “FGF21-associated disorders,” and terms 
similarly used herein, includes but is not limited to obesity, 
type 1 and type 2 diabetes mellitus, pancreatitis, dyslipi 
demia, nonalcoholic steatohepatitis (NASH), insulin resis 
tance, hyperinsulinemia, glucose intolerance, hyperglyce 
mia, metabolic syndrome, hypertension, cardiovascular 
disease, atherosclerosis, peripheral arterial disease, stroke, 
heart failure, coronary heart disease, kidney disease, diabetic 
complications, neuropathy, gastroparesis and other metabolic 
disorders. 
0067. “Type 2 diabetes mellitus' is a condition character 
ized by excess glucose production in spite of the availability 
of insulin, and circulating glucose levels remain excessively 
high as a result of inadequate glucose clearance. 
0068 “Type 1 diabetes mellitus' is a condition character 
ized by high blood glucose levels caused by total lack of 
insulin. This occurs when the body's immune system attacks 
the insulin-producing beta cells in the pancreas and destroys 
them. The pancreas then produces little or no insulin. 
0069. “Pancreatitis” is inflammation of the pancreas. 
0070 “Dyslipidemia' is a disorder of lipoprotein metabo 
lism, including lipoprotein overproduction or deficiency. 
Dyslipidemias may be manifested by elevation of the total 
cholesterol, low-density lipoprotein (LDL) cholesterol and 
triglyceride concentrations, and a decrease in high-density 
lipoprotein (HDL) cholesterol concentration in the blood. 
(0071. “Nonalcoholic steatohepatitis (NASH) is a liver 
disease, not associated with alcohol consumption, character 
ized by fatty change of hepatocytes, accompanied by intral 
obular inflammation and fibrosis. 
0072 "Glucose intolerance.” or Impaired Glucose Toler 
ance (IGT) is a pre-diabetic state of dysglycemia that is asso 
ciated with increased risk of cardiovascular pathology. The 
pre-diabetic condition prevents a Subject from moving glu 
cose into cells efficiently and utilizing it as an efficient fuel 
Source, leading to elevated glucose levels in blood and some 
degree of insulin resistance. 
0073 “Hyperglycemia' is defined as an excess of sugar 
(glucose) in the blood. 
0074 “Hypoglycemia', also called low blood sugar, 
occurs when your blood glucose level drops too low to pro 
vide enough energy for your body's activities. 
0075) “Hyperinsulinemia' is defined as a higher-than-nor 
mal level of insulin in the blood. 
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0.076 “Insulin resistance' is defined as a state in which a 
normal amount of insulin produces a Subnormal biologic 
response. 
0077. “Obesity,” in terms of the human subject, can be 
defined as that body weight over 20 percent above the ideal 
body weight for a given population (R. H. Williams, Textbook 
of Endocrinology, 1974, p. 904-916). 
0078 “Metabolic syndrome” can be defined as a cluster of 
at least three of the following signs: abdominal fat—in most 
men, a 40-inch waist or greater, high blood Sugar—at least 
110 milligrams per deciliter (mg/dl) after fasting; high trig 
lycerides—at least 150 mg/dL in the bloodstream; low 
HDL less than 40 mg/dl; and, blood pressure of 130/85 
mmHg or higher. 
0079) “Hypertension” or high blood pressure that is a tran 
sitory or Sustained elevation of systemic arterial blood pres 
Sure to a level likely to induce cardiovascular damage or other 
adverse consequences. Hypertension has been arbitrarily 
defined as a systolic blood pressure above 140 mmHg or a 
diastolic blood pressure above 90 mmHg. 
0080 “Cardiovascular diseases” are diseases related to the 
heart or blood vessels. 
0081 "Peripheral arterial disease” occurs when plaque 
builds up in the arteries that carry blood to the head, organs 
and limbs. Over time, plaque can harden and narrow the 
arteries which limits the flow of oxygen-rich blood to organs 
and other parts of the body. 
0082 "Atherosclerosis” is a vascular disease character 
ized by irregularly distributed lipid deposits in the intima of 
large and medium-sized arteries, causing narrowing of arte 
rial lumens and proceeding eventually to fibrosis and calcifi 
cation. Lesions are usually focal and progress slowly and 
intermittently. Limitation of blood flow accounts for most 
clinical manifestations, which vary with the distribution and 
severity of lesions. 
0083 “Stroke' is any acute clinical event, related to 
impairment of cerebral circulation, that lasts longer than 24 
hours. A stroke involves irreversible brain damage, the type 
and severity of symptoms depending on the location and 
extent of brain tissue whose circulation has been compro 
mised. 
0084) “Heart failure', also called congestive heart failure, 
is a condition in which the heart can no longer pump enough 
blood to the rest of the body. 
0085 “Coronary heart disease', also called coronary 
artery disease, is a narrowing of the Small blood vessels that 
Supply blood and oxygen to the heart. 
I0086) “Kidney disease' or nephropathy is any disease of 
the kidney. Diabetic nephropathy is a major cause of morbid 
ity and mortality in people with type 1 or type 2 diabetes 
mellitus. 
0087. “Diabetic complications are problems, caused by 
high blood glucose levels, with other body functions such as 
kidneys, nerves (neuropathies), feet (foot ulcers and poor 
circulation) and eyes (e.g. retinopathies). Diabetes also 
increases the risk for heart disease and bone and joint disor 
ders. Other long-term complications of diabetes include skin 
problems, digestive problems, sexual dysfuntion and prob 
lems with teeth and gums. 
0088 “Neuroapathies” are any diseases involving the cra 
nial nerves or the peripheral or autonomic nervous system. 
0089 "Gastroparesis” is weakness of gastric peristalsis, 
which results in delayed emptying of the bowels. 
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0090 The critically ill patients encompassed by the 
present invention generally experience an unstable hyper 
metabolic state. This unstable metabolic state is due to 
changes in Substrate metabolism, which may lead to relative 
deficiencies in some nutrients. Generally there is an increased 
oxidation of both fat and muscle. 
0091 Moreover, critically ill patients are preferably 
patients that experience systemic inflammatory response Syn 
drome or respiratory distress. A reduction in morbidity means 
reducing the likelihood that a critically ill patient will develop 
additional illnesses, conditions, or symptoms or reducing the 
severity of additional illnesses, conditions, or symptoms. For 
example reducing morbidity may correspond to a decrease in 
the incidence of bacteremia or sepsis or complications asso 
ciated with multiple organ failure. 
0092. As used herein, the singular forms “a” “an and 
“the include plural references unless the content clearly 
dictates otherwise. Thus, for example, reference to “an anti 
body' includes a mixture of two or more such antibodies. 
0093. As used herein, the term “about refers to +/-20%, 
+/-10%, or +/-5% of a value. 
0094. The terms “polypeptide' and “protein', are used 
interchangeably and refer to a polymeric form of amino acids 
of any length, which can include coded and non-coded amino 
acids, chemically or biochemically modified or derivatized 
amino acids, and polypeptides having modified peptide back 
bones. The term includes fusion proteins, including, but not 
limited to, fusion proteins with a heterologous amino acid 
sequence, fusions with heterologous and homologous leader 
sequences, with or without N-terminal methionine residues; 
immunologically tagged proteins; and the like. 
(0095. The terms “individual”, “subject”, “host” and 
“patient” are used interchangeably and refer to any subject for 
whom diagnosis, treatment, ortherapy is desired, particularly 
humans. Other subjects may include cattle, dogs, cats, guinea 
pigs, rabbits, rats, mice, horses, and the like. In some pre 
ferred embodiments the subject is a human. 
0096. As used herein, the term “sample” refers to biologi 
cal material from a patient. The sample assayed by the present 
invention is not limited to any particular type. Samples 
include, as non-limiting examples, single cells, multiple cells, 
tissues, tumors, biological fluids, biological molecules, or 
Supernatants or extracts of any of the foregoing. Examples 
include tissue removed for biopsy, tissue removed during 
resection, blood, urine, lymph tissue, lymph fluid, cerebrospi 
nal fluid, mucous, and stool samples. The sample used will 
vary based on the assay format, the detection method and the 
nature of the tumors, tissues, cells or extracts to be assayed. 
Methods for preparing samples are well known in the art and 
can be readily adapted in order to obtain a sample that is 
compatible with the method utilized. 
(0097. As used herein, the term “biological molecule' 
includes, but is not limited to, polypeptides, nucleic acids, and 
saccharides. 
0098. As used herein, the term “modulating refers to a 
change in the quality or quantity of a gene, protein, or any 
molecule that is inside, outside, or on the surface of a cell. The 
change can be an increase or decrease in expression or level of 
the molecule. The term "modulates' also includes changing 
the quality or quantity of a biological function/activity includ 
ing, without limitation, the ability to lower blood glucose, 
insulin, triglyceride, or cholesterol levels; to reduce liver lipid 
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or liver triglyceride levels; to reduce body weight; and to 
improve glucose tolerance, energy expenditure, or insulin 
sensitivity. 
0099. As used herein, the term “modulator refers to a 
composition that modulates one or more physiological or 
biochemical events associated with an FGF21-associated dis 
order, such as type 1 or type 2 diabetes mellitus or a metabolic 
condition like obesity. Said events include but are not limited 
to the ability to lower blood glucose, insulin, triglyceride, or 
cholesterol levels; to reduce liver lipid or liver triglyceride 
levels; to reduce body weight; and to improve glucose toler 
ance, energy expenditure, or insulin sensitivity. 
0100. A “gene product' is a biopolymeric product that is 
expressed or produced by a gene. A gene product may be, for 
example, an unspliced RNA, an mRNA, a splice variant 
mRNA, a polypeptide, a post-translationally modified 
polypeptide, a splice variant polypeptide etc. Also encom 
passed by this term are biopolymeric products that are made 
using an RNA gene product as a template (i.e. cDNA of the 
RNA). A gene product may be made enzymatically, recom 
binantly, chemically, or within a cell to which the gene is 
native. In some embodiments, if the gene product is proteina 
ceous, it exhibits a biological activity. In some embodiments, 
if the gene product is a nucleic acid, it can be translated into 
a proteinaceous gene product that exhibits a biological activ 
ity. 
0101 “Modulation of FGF21 activity,” as used herein, 
refers to an increase or decrease in FGF21 activity that can be 
a result of, for example, interaction of an agent with an FGF21 
polynucleotide or polypeptide, inhibition of FGF21 tran 
Scription and/or translation (e.g., through antisense or siRNA 
interaction with the FGF21 gene or FGF21 transcript, through 
modulation of transcription factors that facilitate FGF21 
expression), and the like. For example, modulation of a bio 
logical activity refers to an increase or a decrease in a bio 
logical activity. FGF21 activity can be assessed by means 
including, without limitation, assaying blood glucose, insu 
lin, triglyceride, or cholesterol levels in a subject, assessing 
FGF21 polypeptide levels, or by assessing FGF21 transcrip 
tion levels. Comparisons of FGF21 activity can also be 
accomplished by, e.g., measuring levels of an FGF21 down 
stream biomarker, and measuring increases in FGF21 signal 
ing. FGF21 activity can also be assessed by measuring: cell 
signaling; kinase activity; glucose uptake into adipocytes; 
blood insulin, triglyceride, or cholesterol level fluctuations: 
liver lipid or liver triglyceride level changes; interactions 
between FGF21 and an FGF21 receptor; or phosphorylation 
ofan FGF21 receptor. In some embodiments phosphorylation 
of an FGF21 receptor can be tyrosine phosphorylation. In 
some embodiments modulation of FGF21 activity can cause 
modulation of an FGF21-related phenotype. 
0102 A“FGF21 downstream biomarker” as used herein, 
is a gene or gene product, or measurable indicia of a gene or 
gene product. In some embodiments, a gene or activity that is 
a downstream marker of FGF21 exhibits an altered level of 
expression, or in a vascular tissue. In some embodiments, an 
activity of the downstream marker is altered in the presence of 
an FGF21 modulator. In some embodiments, the downstream 
markers exhibit altered levels of expression when FGF21 is 
perturbed with an FGF21 modulator of the present invention. 
FGF21 downstream markers include, without limitation, glu 
cose or 2-deoxy-glucose uptake, pERK and other phospho 
rylated or acetylated proteins or NAD levels. 
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0103) As used herein, the term "up-regulates’ refers to an 
increase, activation or stimulation of an activity or quantity. 
For example, in the context of the present invention, FGF21 
modulators may increase the activity of an FGF21 receptor. In 
one embodiment, one or both of FGFR-1c or FGFR-4 may be 
upregulated in response to an FGF21 modulator. Upregula 
tion can also refer to an FGF21-related activity, Such as e.g., 
the ability to lower blood glucose, insulin, triglyceride, or 
cholesterol levels; to reduce liver lipid or triglyceride levels: 
to reduce body weight; to improve glucose tolerance, energy 
expenditure, or insulin sensitivity; or to cause phosphoryla 
tion of an FGF21 receptor; or to increase an FGF21 down 
stream marker. The FGFR21 receptor can be one or both of 
FGFR-1c or FGFR-4. Up-regulation may be at least 25%, at 
least 50%, at least 75%, at least 100%, at least 150%, at least 
200%, at least 250%, at least 400%, or at least 500% as 
compared to a control. 
0104. As used herein, the term “N-terminus’ refers to at 
least the first 10 amino acids of a protein. 
0105. As used herein, the terms “N-terminal domain and 
“N-terminal region' are used interchangeably and refer to a 
fragment of a protein that begins at the first amino acid of the 
protein and ends at any amino acid in the N-terminal half of 
the protein. For example, the N-terminal domain of FGF21 is 
from amino acid 1 of SEQ ID NO:1 to any amino acid 
between about amino acids 10 and 105 of SEQID NO:1. 
0106. As used herein, the term “C-terminus’ refers to at 
least the last 10 amino acids of a protein. 
0107 As used herein, the terms “C-terminal domain” and 
“C-terminal region' are used interchangeably and refer to a 
fragment of a protein that begins at any amino acid in the 
C-terminal half of the protein and ends at the last amino acid 
of the protein. For example, the C-terminal domain of FGF21 
begins at any amino acid from amino acid 105 to about amino 
acid 200 of SEQID NO:1 and ends atamino acid 209 of SEQ 
ID NO:1. 
0108. The term “domain” as used herein refers to a struc 
tural part of a biomolecule that contributes to a known or 
Suspected function of the biomolecule. Domains may be co 
extensive with regions orportions thereofand may also incor 
porate a portion of a biomolecule that is distinct from a 
particular region, in addition to all or part of that region. 
0109 As used herein, the term “signal domain (also 
called 'signal sequence' or 'signal peptide') refers to a pep 
tide domain that resides in a continuous stretch of amino acid 
sequence at the N-terminal region of a precursor protein 
(often a membrane-bound or secreted protein) and is involved 
in post-translational protein transport. In many cases the sig 
nal domain is removed from the full-length protein by spe 
cialized signal peptidases after the sorting process has been 
completed. Each signal domain specifies a particular destina 
tion in the cell for the precursor protein. The signal domain of 
FGF21 is amino acids 1-28 of SEQID NO:1. 
0110. As used herein, the term “receptor binding domain 
refers to any portion or region of a protein that contacts a 
membrane-bound receptor protein, resulting in a cellular 
response, Such as a signaling event. 
0111. As used herein, the term “ligand binding domain 
refers to any portion or region of a protein retaining at least 
one qualitative binding activity of a corresponding native 
sequence of FGF21. 
0112 The term “region” refers to a physically contiguous 
portion of the primary structure of a biomolecule. In the case 
of proteins, a region is defined by a contiguous portion of the 
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amino acid sequence of that protein. In some embodiments a 
“region' is associated with a function of the biomolecule. 
0113. The term “fragment as used herein refers to a 
physically contiguous portion of the primary structure of a 
biomolecule. In the case of proteins, a portion is defined by a 
contiguous portion of the amino acid sequence of that protein 
and refers to at least 3-5 amino acids, at least 8-10 amino 
acids, at least 11-15 amino acids, at least 17-24 amino acids, 
at least 25-30 amino acids, and at least 30-45 amino acids. In 
the case of oligonucleotides, a portion is defined by a con 
tiguous portion of the nucleic acid sequence of that oligo 
nucleotide and refers to at least 9-15 nucleotides, at least 
18-30 nucleotides, at least 33-45 nucleotides, at least 48-72 
nucleotides, at least 75-90 nucleotides, and at least 90-130 
nucleotides. In some embodiments, portions of biomolecules 
have a biological activity. In the context of the present inven 
tion, FGF21 polypeptide fragments do not comprise the entire 
FGF21 polypeptide sequence set forth in SEQID NO:1. 
0114. A “native sequence' polypeptide is one that has the 
same amino acid sequence as a polypeptide derived from 
nature. Such native sequence polypeptides can be isolated 
from nature or can be produced by recombinant or synthetic 
means. Thus, a native sequence polypeptide can have the 
amino acid sequence of naturally occurring human polypep 
tide, murine polypeptide, or polypeptide from any other 
mammalian species. 
0115. As used herein, the phrase “homologous nucleotide 
sequence.” or “homologous amino acid sequence.” or varia 
tions thereof, refers to sequences characterized by a homol 
ogy, at the nucleotide level or amino acid level, of at least a 
specified percentage and is used interchangeably with 
"sequence identity'. Homologous nucleotide sequences 
include those sequences coding for isoforms of proteins. Such 
isoforms can be expressed in different tissues of the same 
organism as a result of for example, alternative splicing of 
RNA. Alternatively, isoforms can be encoded by different 
genes. Homologous nucleotide sequences include nucleotide 
sequences encoding for a protein of a species other than 
humans, including, but not limited to, mammals. Homolo 
gous nucleotide sequences also include, but are not limited to, 
naturally occurring allelic variations and mutations of the 
nucleotide sequences set forth herein. Homologous amino 
acid sequences include those amino acid sequences which 
contain conservative amino acid Substitutions and which 
polypeptides have the same binding and/or activity. In some 
embodiments, a nucleotide or amino acid sequence is 
homologous if it has at least 60%, 70%, 80%, 85%, 90%, 
95%, 96%, 97%, 98%, or 99% identity. In some embodi 
ments, a nucleotide or amino acid sequence is homologous if 
it has 1-10, 10-20, 20-30, 30-40, 40-50, or 50-60 nucleotide? 
amino acid Substitutions, additions, or deletions. In some 
embodiments, the homologous amino acid sequences have no 
more than 5 or no more than 3 conservative amino acid 
substitutes. 
0116 Percent homology or identity can be determined by, 
for example, the Gap program (Wisconsin Sequence Analysis 
Package, Version 8 for UNIX, Genetics Computer Group, 
University Research Park, Madison Wis.), using default set 
tings, which uses the algorithm of Smith and Waterman (Adv. 
Appl. Math., 1981, 2, 482-489). In some embodiments, 
homology between the probe and target is between about 75% 
to about 85%. In some embodiments, nucleic acids have 
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nucleotides that are at least about 95%, about 97%, about 
98%, about 99% and about 100% homologous to SEQ ID 
NO:2, or a portion thereof. 
0117 Homology may also be at the polypeptide level. In 
some embodiments, polypeptides are about 95%, about 97%, 
about 98%, about 99% and about 100% homologous to SEQ 
ID NO:1, or a portion thereof. The degree or percentage 
identity of an FGF21 variant of the present invention (“inven 
tion sequence” e.g. Variant 1 or SEQID NO:5) and a different 
amino acid sequence (“foreign sequence” e.g. SEQID NO:1 
with L174 changed to P174) is calculated as the number of 
exact matches in an alignment of the two sequences divided 
by the length of the “invention sequence' or the “foreign 
sequence', whichever is shortest. The result is expressed as 
percent identity. For example, Variant 1 (SEQID NO:5), has 
94.9% identity to wild type FGF21 with L174 changed to 
P174 (SEQID NO:1 with L174 changed to P174). For these 
two sequences there are 168 identical amino acids and the 
total length is 177 amino acids. Thus, the percent identity is 
(168/177)x100-94.9%. 
0118. As used herein, the term “mixing refers to the 
process of combining one or more compounds, cells, mol 
ecules, and the like together in the same area. This may be 
performed, for example, in a test tube, petri dish, or any 
container that allows the one or more compounds, cells, or 
molecules, to be mixed. 
0119. As used herein, the term “substantially purified’ 
refers to a compound (e.g., either a polynucleotide or a 
polypeptide or an antibody) that is removed from its natural 
environment and is at least 60% free, at least 75% free, and at 
least 90% free from other components with which it is natu 
rally associated. 
0.120. The term “pharmaceutically acceptable carrier' 
refers to a carrier for administration of a therapeutic agent, 
Such as antibodies or a polypeptide, genes, and other thera 
peutic agents. The term refers to any pharmaceutical carrier 
that does not itself induce the production of antibodies harm 
ful to the individual receiving the composition, and which can 
be administered without undue toxicity. Suitable carriers can 
be large, slowly metabolized macromolecules such as pro 
teins, polysaccharides, polylactic acids, polyglycolic acids, 
polymeric amino acids, amino acid copolymers, lipid aggre 
gates and inactive virus particles. Such carriers are well 
known to those of ordinary skill in the art. Pharmaceutically 
acceptable carriers in therapeutic compositions can include 
liquids Such as water, saline, glycerol and ethanol. Auxiliary 
Substances, such as wetting or emulsifying agents, pH buff 
ering Substances, and the like, can also be present in Such 
vehicles. 
I0121 Naturally occurring disulfide bonds, as provided by 
cysteine residues, generally increase thermodynamic stabil 
ity of proteins. Successful examples of increased thermody 
namic stability, as measured in increase of the melting tem 
perature, are multiple disulfide-bonded mutants of the 
enzymes T4 lysozyme (Matsumura, et al., PNAS 86:6562 
6566 (1989)) and barnase (Johnson et al., J. Mol. Biol. 268: 
198-208 (1997)). An aspect of the present invention is an 
enhancement of the physical stability of FGF21 in the pres 
ence of a preservative, achieved by the presence of disulfide 
bonds within the variants, which constrain the flexibility of 
wild type FGF21 and thereby limit access of the preservative 
to the hydrophobic core of the protein. 
0.122 The second aspect of the present invention therefore 
provides variants of human FGF21, or a biologically active 
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Ala162Cys, Asp52Cys-Ala162Cys, Asp53Cys-Ala 162Cys, 
Alaš4Cys-Ala162Cys, Gln55Cys-Ala162Cys, Gln56Cys 
Alal62Cys, Thr57Cys-Ala162Cys, Glu58Cys-Ala162Cys, 
Arg47Cys-Arg163Cys, Tyr18Cys-Arg163Cys, Leu49Cys 
Arg163Cys, TyrSOCys-Arg163Cys, Thr51Cys-Arg163Cys, 
Asp52Cys-Arg163Cys, Asp53Cys-Arg163Cys, Alaš4Cys 
Arg163Cys, Gln55Cys-Arg163Cys, Gln56Cys-Arg163Cys, 
Thr57Cys-Arg163Cys, Glu58Cys-Arg163Cys 
0.125. The third aspect of the present invention provides 
variants of human FGF21, or a biologically active peptide 
thereof, comprising a Substitution of any charged and/or polar 
but uncharged amino acid at any of the amino acid positions 
indicated in the first embodiment of the present invention 
combined with the substitution of a cysteine at two or more 
amino acid positions indicated in the second embodiment of 
the invention. 
0126. It is well known in the art that a significant challenge 
in the development of protein pharmaceuticals is to deal with 
the physical and chemical instabilities of proteins. This is 
even more apparent when a protein pharmaceutical formula 
tion is intended to be a multiple use, injectable formulation 
requiring a stable, concentrated and preserved solution, while 
maintaining a favorable bioactivity profile. Detailed bio 
physical characterization of wild-type FGF21 established 
that a concentrated protein solution (>5 mg/ml), when 
exposed to stress conditions, such as high temperature or low 
pH, lead to accelerated association and aggregation (i.e., poor 
physical stability and biopharmaceutical properties). Expo 
sure of a concentrated protein solution of FGF21 to pharma 
ceutical preservatives (e.g., m-cresol) also had a negative 
impact on physical stability. 
0127. Therefore, an embodiment of the present invention 
is to enhance physical stability of concentrated Solutions, 
while maintaining chemical stability and biological potency, 
under both physiological and preserved formulation condi 
tions. It is thought that association and aggregation may result 
from hydrophobic interactions, since, at a given protein con 
centration, temperature, and ionic strength have considerable 
impact on physical stability. For the most part, non-con 
served, presumed Surface exposed amino acid residues were 
targeted. The local environment of these residues was ana 
lyzed and, those that were not deemed structurally important 
were selected for mutagenesis. One method to initiate specific 
changes is to further decrease the pi of the protein by intro 
ducing glutamic acid residues (glutamic acid scan). It is 
hypothesized that the introduction of charged substitutes 
would inhibit hydrophobic-mediated aggregation via charge 
charge repulsion and potentially improve preservative com 
patibility. In addition, one skilled in the art would also recog 
nize that with sufficient degree of mutagenesis the p could be 
shifted into a basic pH range by the introduction of positive 
charge with or without concomitant decrease in negative 
charge, thus allowing for charge-charge repulsion. 
0128. Although the embodiments of the present invention 
concern the physical and chemical stability under both physi 
ological and preserved pharmaceutical formulation condi 
tions, maintaining the biological potency of the variants as 
compared to wild-type FGF21 is an important factor of con 
sideration as well. Therefore, the biological potency of the 
variants of the present invention is defined by the ability of the 
variants to affect glucose uptake as measured in the in vitro 
3T3-L1 adipocyte 2-DOG uptake cell assay (Example 3) 
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and/or the lowering of plasma glucose levels, as well as, 
plasma triglycerides, as measured in Vivo in the ob?ob mouse 
assay (Example 5). 
I0129. The variants of FGF21 administered according to 
this invention may be generated and/or isolated by any means 
known in the art. The most preferred method for producing 
the variant is through recombinant DNA methodologies and 
is well known to those skilled in the art. Such methods are 
described in Current Protocols in Molecular Biology (John 
Wiley & Sons, Inc.), which is incorporated herein by refer 
CCC. 
0.130. Additionally, the preferred embodiments include a 
biologically active peptide derived from the variant described 
herein. Such a peptide will contain at least one of the substi 
tutions described and the variant will possess biological activ 
ity. The peptide may be produced by any and all means known 
to those skilled in the art, examples of which included but are 
not limited to enzymatic digestion, chemical synthesis or 
recombinant DNA methodologies. 
I0131. It is established in the art that fragments of peptides 
of certain fibroblast growth factors are biologically active. 
See for example, Baird et al., Proc. Natl. Acad. Sci. (USA) 
85:2324-2328 (1988), and J. Cell. Phys. Suppl. 5:101-106 
(1987). Therefore, the selection of fragments or peptides of 
the variant is based on criteria known in the art. For example, 
it is known that dipeptidyl peptidase IV (DPP-IV) is a serine 
type protease involved in inactivation of neuropeptides, endo 
crine peptides, and cytokines (Damme et al. Chem. Immunol. 
72:42-56, (1999)). The N-terminus of FGF21 (HisProlePro) 
contains two dipeptides that could potentially be substrates to 
DPP-IV, resulting in a fragment of FGF21 truncated at the 
N-terminus by 4 amino acids. Unexpectedly, this fragment of 
wild-type FGF21 has been demonstrated to retain biological 
activity (Table 2), thus, variants of the present invention trun 
cated at the N-terminus by up to 4 amino acids, is an embodi 
ment of the present invention. 
0.132. The invention also encompasses polynucleotides 
encoding the above-described variants that may be in the 
form of RNA or in the form of DNA, which DNA includes 
cDNA, genomic DNA, and synthetic DNA. The DNA may be 
double-stranded or single-stranded. The coding sequences 
that encode the variants of the present invention may vary as 
a result of the redundancy or degeneracy of the genetic code. 
I0133. The polynucleotides that encode for the variants of 
the invention may include the following: only the coding 
sequence for the variant, the coding sequence for the variant 
and additional coding sequence Such as a functional polypep 
tide, or a leader or secretory sequence or a pro-protein 
sequence; the coding sequence for the variant and non-coding 
sequence, such as introns or non-coding sequence 5' and/or 3' 
of the coding sequence for the variant. Thus the term “poly 
nucleotide encoding a variant' encompasses a polynucleotide 
that may include not only coding sequence for the variant but 
also a polynucleotide, which includes additional coding and/ 
or non-coding sequence. 
0.134. The invention further relates to variants of the 
described polynucleotides that encode for fragments, analogs 
and derivatives of the polypeptide that contain the indicated 
substitutions. The variant of the polynucleotide may be a 
naturally occurring allelic variant of the human FGF21 
sequence, a non-naturally occurring variant, or a truncated 
variant as described above. Thus, the present invention also 
includes polynucleotides encoding the variants described 
above, as well as variants of Such polynucleotides, which 
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variants encode for a fragment, derivative or analog of the 
disclosed variant. Such nucleotide variants include deletion 
variants, Substitution variants, truncated variants, and addi 
tion or insertion variants as long as at least one of the indicated 
amino acid Substitutions of the first or second embodiments is 
present. 
0135. The polynucleotides of the invention will be 
expressed in hosts after the sequences have been operably 
linked to (i.e., positioned to ensure the functioning of) an 
expression control sequence. These expression vectors are 
typically replicable in the host organisms either as episomes 
or as an integral part of the host chromosomal DNA. Com 
monly, expression vectors will contain selection markers, 
e.g., tetracycline, neomycin, and dihydrofolate reductase, to 
permit detection of those cells transformed with the desired 
DNA sequences. The FGF21 variant can be expressed in 
mammalian cells, insect, yeast, bacterial or other cells under 
the control of appropriate promoters. Cell free translation 
systems can also be employed to produce Such proteins using 
RNAs derived from DNA constructs of the present invention. 
0.136 E. coli is a prokaryotic host useful particularly for 
cloning the polynucleotides of the present invention. Other 
microbial hosts suitable for use include Bacillus subtilus, 
Salmonella typhimurium, and various species of Serratia, 
Pseudomonas, Streptococcus, and Staphylococcus, although 
others may also be employed as a matter of choice. In these 
prokaryotic hosts, one can also make expression vectors, 
which will typically contain expression control sequences 
compatible with the host cell (e.g., an origin of replication). In 
addition, any of a number of well-known promoters may be 
present, such as the lactose promoter system, a tryptophan 
(trp) promoter system, a beta-lactamase promoter system, or 
a promoter system from phages lambda or T7. The promoters 
will typically control expression, optionally with an operator 
sequence, and have ribosome binding site sequences and the 
like, for initiating and completing transcription and transla 
tion. 
0.137. One skilled in the art of expression of proteins will 
recognize that methionine or methionine-arginine sequence 
can be introduced at the N-terminus of the mature sequence 
(SEQ ID NO: 3) for expression in E. coli and are contem 
plated within the context of this invention. Thus, unless oth 
erwise noted, variants of the present invention expressed in E. 
coli have a methionine sequence introduced at the N-termi 
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0.138. Other microbes, such as yeast or fungi, may also be 
used for expression. Pichia pastoris, Saccharomyces cerevi 
siae, Schizosaccharomyces pombe, and Pichia angusta are 
examples of preferred yeast hosts, with suitable vectors hav 
ing expression control sequences, such as promoters, includ 
ing 3-phosphoglycerate kinase or other glycolytic enzymes, 
and an origin of replication, termination sequences and the 
like as desired. Aspergillus niger; Trichoderma reesei; and 
Schizophyllum commune, are examples of fungi hosts, 
although others may also be employed as a matter of choice. 
0139 Mammalian tissue cell culture may also be used to 
express and produce the polypeptides of the present inven 
tion. Eukaryotic cells are actually preferred, because a num 
ber of suitable host cell lines capable of secreting intact vari 
ants have been developed in the art, and include the CHO cell 
lines, various COS cell lines, NSO cells, Syrian Hamster 
Ovary cell lines, HeLa cells, or human embryonic kidney cell 
lines (i.e. HEK293, HEK293EBNA). 
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0140 Expression vectors for these cells can include 
expression control sequences, such as an origin of replication, 
a promoter, an enhancer, and necessary processing informa 
tion sites, such as ribosome binding sites, RNA splice sites, 
polyadenylation sites, and transcriptional terminator 
sequences. Preferred expression control sequences are pro 
moters derived from SV40, adenovirus, bovine papilloma 
virus, cytomegalovirus, Raus sarcoma virus, and the like. 
Preferred polyadenylation sites include sequences derived 
from SV40 and bovine growth hormone. 
0.141. The vectors containing the polynucleotide 
sequences of interest (e.g., the variants of FGF21 and expres 
sion control sequences) can be transferred into the host cell by 
well-known methods, which vary depending on the type of 
cellular host. For example, calcium chloride transfection is 
commonly utilized for prokaryotic cells, whereas calcium 
phosphate treatment or electroporation may be used for other 
cellular hosts. 
0.142 Various methods of protein purification may be 
employed and Such methods are known in the art and 
described, for example, in Deutscher, Methods in Enzymol 
ogy 182: 83-9 (1990) and Scopes, Protein Purification: Prin 
ciples and Practice, Springer-Verlag, NY (1982). The purifi 
cation step(s) selected will depend, for example, on the nature 
of the production process used for the variants of FGF21. 
0143. The FGF21 variant-containing compositions should 
be formulated and dosed in a fashion consistent with good 
medical practice, taking into account the clinical condition of 
the patient, the site of delivery of the FGF21 variant compo 
sition, the method of administration, the scheduling of admin 
istration, and other factors known to practitioners. The “thera 
peutically effective amount of the FGF21 variant for 
purposes herein is thus determined by Such considerations. 
0144. The pharmaceutical compositions of the FGF21 
variants and of the present invention may be administered by 
any means that achieve the generally intended purpose: to 
treat type 1 and type 2 diabetes mellitus, obesity, metabolic 
syndrome, or critically ill patients. The term “parenteral as 
used herein refers to modes of administration that include 
intravenous, intramuscular, intraperitoneal, intrasternal, Sub 
cutaneous, and intraarticular injection and infusion. The dos 
age administered will be dependent upon the age, health, and 
weight of the recipient, kind of concurrent treatment, if any, 
frequency of treatment, and the nature of the effect desired. 
Compositions within the scope of the invention include all 
compositions wherein an FGF21 variant is present in an 
amount that is effective to achieve the desired medical effect 
for treatment type 1 or type 2 diabetes mellitus, obesity, or 
metabolic syndrome. While individual needs may vary from 
one patient to another, the determination of the optimal ranges 
of effective amounts of all of the components is within the 
ability of the clinician of ordinary skill. 
0145 The variants of FGF21 of the present invention can 
be formulated according to known methods to prepare phar 
maceutically useful compositions. A desired formulation 
would be one that is a stable lyophilized product that is 
reconstituted with an appropriate diluent or an aqueous solu 
tion of high purity with optional pharmaceutically acceptable 
carriers, preservatives, excipients or stabilizers Remington's 
Pharmaceutical Sciences 16th edition (1980). The variants 
of the present invention may be combined with a pharmaceu 
tically acceptable buffer, and the pH adjusted to provide 
acceptable stability, and a pH acceptable for administration. 
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0146 For parenteral administration, in one embodiment, 
the FGF21 variants are formulated generally by mixing one or 
more of them at the desired degree of purity, in a unit dosage 
injectable form (solution, Suspension, or emulsion), with a 
pharmaceutically acceptable carrier, i.e., one that is non-toxic 
to recipients at the dosages and concentrations employed and 
is compatible with other ingredients of the formulation. Pref 
erably, one or more pharmaceutically acceptable anti-micro 
bial agents may be added. Phenol, m-cresol, and benzyl alco 
hol are preferred pharmaceutically acceptable anti-microbial 
agents. 
0147 Optionally, one or more pharmaceutically accept 
able salts may be added to adjust the ionic strength or tonicity. 
One or more excipients may be added to further adjust the 
isotonicity of the formulation. Glycerin, sodium chloride, and 
mannitol are examples of an isotonicity adjusting excipient. 
0148 Those skilled in the art can readily optimize phar 
maceutically effective dosages and administration regimens 
for therapeutic compositions comprising an FGF21 variant, 
as determined by good medical practice and the clinical con 
dition of the individual patient. A typical dose range for the 
FGF21 variants of the present invention will range from about 
0.01 mg per day to about 1000 mg per day (or about 0.05 mg 
per week to about 5000 mg per week administered once per 
week) for an adult. Preferably, the dosage ranges from about 
0.1 mg per day to about 100 mg per day (or about 0.5 mg per 
week to about 500 mg per week adminstered once per week), 
more preferably from about 1.0 mg/day to about 10 mg/day 
(or about 5 mg per week to about 50 mg per week adminis 
tered once per week). Most preferably, the dosage is about 1-5 
mg/day (or about 5 mg per week to about 25 mg per week 
administered once per week). The appropriate dose of an 
FGF21 variant administered will result in lowering blood 
glucose levels and increasing energy expenditure by faster 
and more efficient glucose utilization, and thus is useful for 
treating type 1 and type 2 diabetes mellitus, obesity and 
metabolic syndrome. 
0149. In addition, because hyperglycemia and insulin 
resistance are common in critically ill patients given nutri 
tional Support, Some ICUs administer insulin to treat exces 
sive hyperglycemia in fed critically ill patients. In fact, recent 
studies document the use of exogenous insulin to maintain 
blood glucose at a level no higher than 110 mg per deciliter 
reduced morbidity and mortality among critically ill patients 
in the Surgical intensive care unit, regardless of whether they 
had a history of diabetes (Van den Berghe, et al. N Engl J. 
Med., 345(19): 1359, (2001)). Thus, variants of FGF21 of the 
present invention are uniquely Suited to help restore meta 
bolic stability in metabolically unstable critically ill patients. 
Variants of FGF21 are unique in that they stimulate glucose 
uptake and enhances insulin sensitivity but do not induce 
hypoglycemia. 
0150. In another aspect of the present invention, variants 
of FGF21 for use as a medicament for the treatment of type 1 
and type 2 diabetes mellitus, obesity, metabolic syndrome, or 
critically ill patients is contemplated. 
0151. Having now described the present invention in 
detail, the same will be more clearly understood by reference 
to the following examples, which are included herewith for 
purposes of illustration only and are not intended to be lim 
iting of the invention. 
0152 The practice of the present invention will employ, 
unless otherwise indicated, conventional methods of chemis 
try, biochemistry, molecular biology, immunology and phar 
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macology, within the skill of the art. Such techniques are 
explained fully in the literature. See, e.g., Remington's Phar 
maceutical Sciences, 18th Edition (Easton, Pa.; Mack Pub 
lishing Company, 1990); Methods In Enzymology (S. Colow 
ick and N. Kaplan, eds., Academic Press, Inc.); and 
Handbook of Experimental Immunology, Vols. I-IV (D. M. 
Weir and C. C. Blackwell, eds., 1986, Blackwell Scientific 
Publications); and Sambrook et al., Molecular Cloning: A 
Laboratory Manual (2nd Edition, 1989). 
Site-Specific FGF21 Mutants 
0153. The term “site-specific FGF21 mutant” or “substi 
tuted FGF21 mutant” refers to an FGF21 mutant polypeptide 
having an amino acid sequence that differs from the amino 
acid sequence of a naturally occurring FGF21 polypeptide 
sequence, e.g., SEQID NO:1 and variants thereof. Site-spe 
cific FGF21 mutants can be generated by introducing amino 
acid substitutions, either conservative or non-conservative 
and using naturally or non-naturally occurring amino acids, at 
particular positions of the FGF21 polypeptide. 
0154 “Conservative amino acid substitution can involve 
a Substitution of a native amino acid residue (i.e., a residue 
found in a given position of the wild-type FGF21 polypeptide 
sequence) with a normative residue (i.e., a residue that is not 
found in a given position of the wild-type FGF21 polypeptide 
sequence) such that there is little or no effect on the polarity or 
charge of the amino acid residue at that position. Conserva 
tive amino acid Substitutions also encompass non-naturally 
occurring amino acid residues that are typically incorporated 
by chemical peptide synthesis rather than by synthesis in 
biological systems. These include peptidomimetics, and 
other reversed or inverted forms of amino acid moieties. 
0155 Naturally occurring residues can be divided into 
classes based on common side chain properties: 
0156 (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile: 
(O157 (2) neutral hydrophilic: Cys, Ser, Thr: 
0158 (3) acidic: Asp, Glu: 
0159 (4) basic: Asn., Gln, H is, Lys, Arg; 
0160 (5) residues that influence chain orientation: Gly, 
Pro; 
0.161 (6) aromatic: Trp, Tyr, Phe; and 
0162 (7) selenocysteine, pyrrolysine (PYL), and pyrro 
line-carboxy-lysine (PCL). 
0163 Conservative substitutions can involve the exchange 
of a member of one of these classes for another member of the 
same class. Non-conservative Substitutions can involve the 
exchange of a member of one of these classes for a member 
from another class. 
0164. Desired amino acid substitutions (whether conser 
vative or non-conservative) can be determined by those 
skilled in the art at the time such substitutions are desired. 
Truncated FGF21 Polypeptides 
0.165. One embodiment of the present invention is directed 
to truncated forms of the mature FGF21 polypeptide (SEQID 
NO:3). This embodiment of the present invention arose from 
an effort to identify truncated FGF21 polypeptides that are 
capable of providing an activity that is similar, and in some 
instances superior, to untruncated forms of the mature FGF21 
polypeptide. 
(0166 As used herein, the term “truncated FGF21 
polypeptide' refers to an FGF21 polypeptide in which amino 
acid residues have been removed from the amino-terminal (or 
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N-terminal) end of the FGF21 polypeptide, amino acid resi 
dues have been removed from the carboxyl-terminal (or 
C-terminal) end of the FGF21 polypeptide, or amino acid 
residues have been removed from both the amino-terminal 
and carboxyl-terminal ends of the FGF21 polypeptide. The 
various truncations disclosed herein were prepared as 
described herein. 
(0167. The activity of N-terminally truncated FGF21 
polypeptides and C-terminally truncated FGF21 polypep 
tides can be assayed using an in vitro phospho-ERK assay. 
Specific details of the in vitro assays that can be used to 
examine the activity of truncated FGF21 polypeptides can be 
found in the examples. 
0168 The activity of the truncated FGF21 polypeptides of 
the present invention can also be assessed in an in vivo assay, 
such as ob/ob mice. Generally, to assess the in vivo activity of 
a truncated FGF21 polypeptide, the truncated FGF21 
polypeptide can be administered to a test animal intraperito 
neally. After a desired incubation period (e.g., one hour or 
more), a blood sample can be drawn, and blood glucose levels 
can be measured. 
0169. a. N-Terminal Truncations 
0170 In some embodiments of the present invention, 
N-terminal truncations comprise 1, 2, 3, 4, 5, 6, 7, or 8 amino 
acid residues from the N-terminal end of the mature FGF21 
polypeptide. Truncated FGF21 polypeptides having N-termi 
nal truncations offewer than 9 amino acid residues retain the 
ability of the mature FGF21 polypeptide to lower blood glu 
cose in an individual. Accordingly, in particular embodi 
ments, the present invention encompasses truncated forms of 
the mature FGF21 polypeptide or FGF21 protein variants 
having N-terminal truncations of 1,2,3,4, 5, 6, 7, or 8 amino 
acid residues. 
0171 b. C-Terminal Truncations 
0172. In some embodiments of the present invention, 
C-terminal truncations comprise 1,2,3,4,5,6,7,8,9, 10, 11, 
or 12 amino acid residues from the C-terminal end of the 
mature FGF21 polypeptide. Truncated FGF21 polypeptides 
having C-terminal truncations of fewer than 13 amino acid 
residues exhibited an efficacy of at least 50% of the efficacy of 
wild-type FGF21 in an in vitro ELK-luciferase assay (Yie J. et 
al. FEBS Letts 583:19-24 (2009)), indicating that these 
FGF21 mutants retain the ability of the mature FGF21 
polypeptide to lower blood glucose in an individual. Accord 
ingly, in particular embodiments, the present invention 
encompasses truncated forms of the mature FGF21 polypep 
tide or FGF21 protein variants having C-terminal truncations 
of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues. 
0173 c. N-Terminal and C-Terminal Truncations 
0.174. In some embodiments of the present invention, trun 
cated FGF21 polypeptides can have a combination of N-ter 
minal and C-terminal truncations. Truncated FGF21 
polypeptides having a combination of N-terminal and C-ter 
minal truncations share the activity of corresponding trun 
cated FGF21 polypeptides having either the N-terminal or 
C-terminal truncations alone. In other words, truncated 
FGF21 polypeptides having both N-terminal truncations of 
fewer than 9 amino acid residues and C-terminal truncations 
of fewer than 13 amino acid residues possess similar or 
greater blood glucose-lowering activity as truncated FGF21 
polypeptides having N-terminal truncations of fewer than 9 
amino acid residues or truncated FGF21 polypeptides having 
C-terminal truncations offewer than 13 amino acid residues. 
Accordingly, in particular embodiments, the present inven 
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tion encompasses truncated forms of the mature FGF21 
polypeptide or FGF21 protein variants having both N-termi 
nal truncations of 1, 2, 3, 4, 5, 6, 7, or 8 amino acid residues 
and C-terminal truncations of 1,2,3,4,5,6,7,8,9, 10, 11, or 
12 amino acid residues. 
(0175. As with all FGF21 variants of the present invention, 
truncated FGF21 polypeptides can optionally comprise an 
amino-terminal methionine residue, which can be introduced 
by directed mutation or as a result of a bacterial expression 
process. 
0176 The truncated FGF21 polypeptides of the present 
invention can be prepared as described in the examples 
described herein. Those of ordinary skill in the art, familiar 
with Standard molecular biology techniques, can employ that 
knowledge, coupled with the instant disclosure, to make and 
use the truncated FGF21 polypeptides of the present inven 
tion. Standard techniques can be used for recombinant DNA, 
oligonucleotide synthesis, tissue culture, and transformation 
(e.g., electroporation, lipofection). See, e.g., Sambrook et al., 
Molecular Cloning: A Laboratory Manual, supra, which is 
incorporated herein by reference for any purpose. Enzymatic 
reactions and purification techniques can be performed 
according to manufacturer's specifications, as commonly 
accomplished in the art, or as described herein. Unless spe 
cific definitions are provided, the nomenclatures utilized in 
connection with, and the laboratory procedures and tech 
niques of analytical chemistry, synthetic organic chemistry, 
and medicinal and pharmaceutical chemistry described 
herein are those well known and commonly used in the art. 
Standard techniques can be used for chemical syntheses; 
chemical analyses; pharmaceutical preparation, formulation, 
and delivery; and treatment of patients. 
(0177. The truncated FGF21 polypeptides of the present 
invention can also be fused to another entity, which can 
impart additional properties to the truncated FGF21 polypep 
tide. In one embodiment of the present invention, a truncated 
FGF21 polypeptide can be fused to an IgG constant domain or 
fragment thereof (e.g., the Fc region), Human Serum Albu 
min (HSA), or albumin-binding polypeptides. Such fusion 
can be accomplished using known molecular biological 
methods and/or the guidance provided herein. The benefits of 
Such fusion polypeptides, as well as methods for making Such 
fusion polypeptides, are discussed in more detail herein. 
FGF21 Fusion Proteins 
0.178 As used herein, the term “FGF21 fusion polypep 
tide' or “FGF21 fusion protein’ refers to a fusion of one or 
more amino acid residues (such as a heterologous protein or 
peptide) at the N-terminus or C-terminus of any FGF21 pro 
tein variant described herein. 
0179 Heterologous peptides and polypeptides include, 
but are not limited to, an epitope to allow for the detection 
and/or isolation of an FGF21 protein variant; a transmem 
brane receptor protein or a portion thereof. Such as an extra 
cellular domain or a transmembrane and intracellular 
domain; a ligand or a portion thereof which binds to a trans 
membrane receptor protein; an enzyme or portion thereof 
which is catalytically active; a polypeptide or peptide which 
promotes oligomerization, such as a leucine Zipper domain; a 
polypeptide or peptide which increases stability, Such as an 
immunoglobulin constant region; a functional or non-func 
tional antibody, or a heavy or light chain thereof, and a 
polypeptide which has an activity, Such as a therapeutic activ 
ity, different from the FGF21 protein variants of the present 
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invention. Also encompassed by the present invention are 
FGF21 mutants fused to human serum albumin (HSA). 
0180 FGF21 fusion proteins can be made by fusing het 
erologous sequences at either the N-terminus or at the C-ter 
minus of an FGF21 protein variant. As described herein, a 
heterologous sequence can be an amino acid sequence or a 
non-amino acid-containing polymer. Heterologous 
sequences can be fused either directly to the FGF21 protein 
variant or via a linker or adapter molecule. A linker or adapter 
molecule can be one or more amino acid residues (or-mers), 
e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 residues (or -mers), preferably 
from 10 to 50 amino acid residues (or-mers), e.g., 10, 11, 12, 
13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 residues 
(or -mers), and more preferably from 15 to 35 amino acid 
residues (or-mers). A linker or adapter molecule can also be 
designed with a cleavage site for a DNA restriction endonu 
clease or for a protease to allow for the separation of the fused 
moieties. 
0181 
0182. In one embodiment of the present invention, an 
FGF21 protein variant is fused to one or more domains of an 
Fc region of human IgG. Antibodies comprise two function 
ally independent parts, a variable domain known as “Fab.” 
that binds an antigen, and a constant domain known as "Fc. 
that is involved in effector functions such as complement 
activation and attack by phagocytic cells. An Fc has a long 
serum half-life, whereas a Fab is short-lived (Capon et al., 
1989, Nature 337: 525-31). When joined together with a 
therapeutic protein, an Fc domain can provide longer half-life 
or incorporate Such functions as Fc receptor binding, protein 
A binding, complement fixation, and perhaps even placental 
transfer (Capon et al., 1989). 
0183 In vivo pharmacokinetic analysis indicated that 
human FGF21 has a short half-life of about 0.5 to 1 hours in 
mice due to rapid clearance and in vivo degradation. There 
fore, to extend the half-life of FGF21 an Fc sequence was 
fused to the N- or C-terminal end of the FGF21 polypeptide. 
The fusion of an Fc region to wild-type FGF21, in particularly 
Fc fused to the N-terminus of wild-type FGF21, did not 
extend the half-life as expected, however, which led to an 
investigation of the proteolytic degradation of FGF21 in vivo 
and the identification of FGF21 mutants that were resistant to 
Such degradation. 
0184 Throughout the disclosure, Fc-FGF21 refers to a 
fusion protein in which the Fc sequence is fused to the N-ter 
minus of FGF21. Similarly, throughout the disclosure, 
FGF21-Fc refers to a fusion protein in which the Fc sequence 
is fused to the C-terminus of FGF21. 
0185. The resulting FGF21 fusion protein can be purified, 
for example, by the use of a Protein A affinity column. Pep 
tides and proteins fused to an Fc region have been found to 
exhibit a substantially greater half-life in vivo than the 
unfused counterpart. Also, a fusion to an Fc region allows for 
dimerization/multimerization of the fusion polypeptide. The 
Fc region can be a naturally occurring Fc region, or can be 
altered to improve certain qualities, such as therapeutic quali 
ties, circulation time, or reduced aggregation. 
0186. Useful modifications of protein therapeutic agents 
by fusion with the “Fc domain of an antibody are discussed 
in detail in International Publication No. WO 00/024782, 
which is hereby incorporated by reference in its entirety. This 
document discusses linkage to a "vehicle'. Such as polyethyl 
ene glycol (PEG), dextran, or an Fc region. 
a. Fc Fusions 
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0187 b. Fusion Protein Linkers 
0188 When forming the fusion proteins of the present 
invention, a linker can, but need not, be employed. When 
present, the linker's chemical structure may not critical, since 
it serves primarily as a spacer. The linker can be made up of 
amino acids linked together by peptide bonds. In some 
embodiments of the present invention, the linker is made up 
of from 1 to 20 amino acids linked by peptide bonds, wherein 
the amino acids are selected from the 20 naturally occurring 
amino acids. In various embodiments, the 1 to 20 amino acids 
are selected from the amino acids glycine, serine, alanine, 
proline, asparagine, glutamine, and lysine. In some embodi 
ments, a linker is made up of a majority of amino acids that are 
sterically unhindered, such as glycine and alanine. In some 
embodiments, linkers are polyglycines, polyalanines, combi 
nations of glycine and alanine (such as poly(Gly-Ala)), or 
combinations of glycine and serine (such as poly(Gly-Ser)). 
While a linker of 15 amino acid residues has been found to 
work particularly well for FGF21 fusion proteins, the present 
invention contemplates linkers of any length or composition. 
0189 The linkers described herein are exemplary, and 
linkers that are much longer and which include other residues 
are contemplated by the present invention. Non-peptide link 
ers are also contemplated by the present invention. For 
example, alkyl linkers such as can be used. These alkyl linkers 
can further be substituted by any non-sterically hindering 
group, including, but not limited to, a lower alkyl (e.g., 
C1-C6), lower acyl, halogen (e.g., Cl, Br), CN. NH2, or 
phenyl. An exemplary non-peptide linker is a polyethylene 
glycol linker, wherein the linker has a molecular weight of 
100 to 5000 kD, for example, 100 to 500 kD. 
Chemically-Modified FGF21 Mutants 
(0190. Chemically modified forms of the FGF21 protein 
variants described herein, including the truncated forms of 
FGF21 described herein, can be prepared by one skilled in the 
art, given the disclosures described herein. Such chemically 
modified FGF21 mutants are altered such that the chemically 
modified FGF21 mutant is different from the unmodified 
FGF21 mutant, either in the type or location of the molecules 
naturally attached to the FGF21 mutant. Chemically modified 
FGF21 mutants can include molecules formed by the deletion 
of one or more naturally-attached chemical groups. 
0191 In one embodiment, FGF21 protein variants of the 
present invention can be modified by the covalent attachment 
of one or more polymers. For example, the polymer selected 
is typically water-soluble so that the protein to which it is 
attached does not precipitate inanaqueous environment, Such 
as a physiological environment. Included within the scope of 
suitable polymers is a mixture of polymers. Preferably, for 
therapeutic use of the end-product preparation, the polymer 
will be pharmaceutically acceptable. Non-water soluble 
polymers conjugated to FGF21 protein variants of the present 
invention also form an aspect of the invention. 
0.192 Exemplary polymers each can be of any molecular 
weight and can be branched or unbranched. The polymers 
each typically have an average molecular weight of between 
about 2 kDa to about 100 kDa (the term “about indicating 
that in preparations of a water-soluble polymer, Some mol 
ecules will weigh more and some less than the stated molecu 
lar weight). The average molecular weight of each polymer is 
preferably between about 5 kDa and about 50 kDa, more 
preferably between about 12 kDa and about 40kDa, and most 
preferably between about 20 kDa and about 35 kDa. 
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0193 Suitable water-soluble polymers or mixtures thereof 
include, but are not limited to, N-linked or O-linked carbo 
hydrates, Sugars, phosphates, polyethylene glycol (PEG) (in 
cluding the forms of PEG that have been used to derivatize 
proteins, including mono-(C1-C10), alkoxy-, or aryloxy 
polyethylene glycol), monomethoxy-polyethylene glycol, 
dextran (Such as low molecular weight dextran of for 
example, about 6 kD), cellulose, or other carbohydrate based 
polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, 
propylene glycol homopolymers, polypropylene oxide/ethyl 
ene oxide co-polymers, polyoxyethylated polyols (e.g., glyc 
erol), and polyvinyl alcohol. Also encompassed by the 
present invention are bifunctional crosslinking molecules 
that can be used to prepare covalently attached FGF21 protein 
variant multimers. Also encompassed by the present inven 
tion are FGF21 mutants covalently attached to polysialic 
acid. 
0194 In some embodiments of the present invention, an 
FGF21 mutant is covalently, or chemically, modified to 
include one or more water-soluble polymers, including, but 
not limited to, polyethylene glycol (PEG), polyoxyethylene 
glycol, or polypropylene glycol. See, e.g., U.S. Pat. Nos. 
4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791, 192; and 
4,179,337. In some embodiments of the present invention, an 
FGF21 mutant comprises one or more polymers, including, 
but not limited to, monomethoxy-polyethylene glycol, dext 
ran, cellulose, another carbohydrate-based polymer, poly-(N- 
vinyl pyrrolidone)-polyethylene glycol, propylene glycol 
homopolymers, a polypropylene oxide/ethylene oxide co 
polymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl 
alcohol, or mixtures of such polymers. 
0.195. In some embodiments of the present invention, an 
FGF21 mutant is covalently-modified with PEG subunits. In 
Some embodiments, one or more water-soluble polymers are 
bonded at one or more specific positions (for example, at the 
N-terminus) of the FGF21 mutant. In some embodiments, 
one or more water-soluble polymers are randomly attached to 
one or more side chains of an FGF21 mutant. In some 
embodiments, PEG is used to improve the therapeutic capac 
ity of an FGF21 mutant. Certain such methods are discussed, 
for example, in U.S. Pat. No. 6,133,426, which is hereby 
incorporated by reference for any purpose. 
0196. In embodiments of the present invention wherein 
the polymer is PEG, the PEG group can be of any convenient 
molecular weight, and can be linear or branched. The average 
molecular weight of the PEG group will preferably range 
from about 2 kD to about 100 kDa, and more preferably from 
about 5 kDa to about 50 kDa, e.g., 10, 20, 30, 40, or 50 kDa. 
The PEG groups will generally be attached to the FGF21 
mutant via acylation or reductive alkylation through a reac 
tive group on the PEG moiety (e.g., an aldehyde, amino, thiol, 
or ester group) to a reactive group on the FGF21 mutant (e.g., 
an aldehyde, amino, or ester group). 
0.197 Branched PEG derivatives, also known as 
“Y-shaped PEG derivatives, contain two linear methoxy 
PEG chain attached to a central core. The sterically bulky 
structure of these “Y-shaped” PEG derivatives will facilitate 
the single point attachment of the modified molecules. By 
way of example, three kinds of “Y-shaped PEG derivatives 
are Y-NHS-40K (useful foramine PEGylation);Y-MAL-40K 
(useful for thiol PEGylation); and Y-ALD-40K (e.g., 
Y-AALD-40K and Y-PALD-40K)(useful for N-terminal 
PEGylation). For amine PEGylation, the “Y-shape' NHS 
ester will react with the amino group of lysine(s) or the 
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N-terminal amine in biological active molecules to produce a 
stable amide linkage(s). This NHS ester will couple with the 
targeted molecules at pH 7-8. For thiol PEGylation, the 
“Y-shape' maleimide will react with the thiol groups in bio 
logical active molecules to generates a stable 3-thiosuccin 
imidyl ether linkage. This maleimide will couple with the 
targeted molecules at pH 5.0-6.5 in the presence of other 
functional groups. For N-terminal PEGylation, The 
“Y-shape' aldehyde will preferably react with the N-terminal 
amine in biological active molecules to produce a stable 
amine linkage in the presence of a reducing reagent such as 
sodium cyanoborohydride. This aldehyde will couple with 
the N-terminal amine of the targeted molecules at pH 5-8. 
Reagents for performing branched PEGylation are available 
through, e.g., Jenkem Technology. 
0198 The PEGylation of a polypeptide, including the 
FGF21 mutants of the present invention, can be specifically 
carried out using any of the PEGylation reactions known in 
the art. Such reactions are described, for example, in the 
following references: Francis et al., 1992, Focus on Growth 
Factors 3: 4-10; European Patent Nos. 0 154316 and 0.401 
384; and U.S. Pat. No. 4,179,337. For example, PEGylation 
can be carried out via an acylation reaction or an alkylation 
reaction with a reactive polyethylene glycol molecule (or an 
analogous reactive water-soluble polymer) as described 
herein. For the acylation reactions, a selected polymer should 
have a single reactive ester group. For reductive alkylation, a 
selected polymer should have a single reactive aldehyde 
group. A reactive aldehyde is, for example, polyethylene gly 
col propionaldehyde, which is water stable, or mono C1-C10 
alkoxy or aryloxy derivatives thereof (see, e.g., U.S. Pat. No. 
5,252,714). 
0199. In some embodiments of the present invention, a 
useful strategy for the attachment of the PEG group to a 
polypeptide involves combining, through the formation of a 
conjugate linkage in Solution, a peptide and a PEG moiety, 
each bearing a special functionality that is mutually reactive 
toward the other. The peptides can be easily prepared with 
conventional Solid phase synthesis. The peptides are “preac 
tivated with an appropriate functional group at a specific site. 
The precursors are purified and fully characterized prior to 
reacting with the PEG moiety. Ligation of the peptide with 
PEG usually takes place in aqueous phase and can be easily 
monitored by reverse phase analytical HPLC. The PEGylated 
peptides can be easily purified by preparative HPLC and 
characterized by analytical HPLC, amino acid analysis and 
laser desorption mass spectrometry. 
0200 Polysaccharide polymers are another type of water 
soluble polymer that can be used for protein modification. 
Therefore, the FGF21 mutants of the present invention fused 
to a polysaccharide polymer form embodiments of the 
present invention. Dextrans are polysaccharide polymers 
comprised of individual subunits of glucose predominantly 
linked by alpha 1-6 linkages. The dextran itself is available in 
many molecular weight ranges, and is readily available in 
molecular weights from about 1 kD to about 70 kD. Dextran 
is a suitable water-soluble polymer for use as a vehicle by 
itself or in combination with another vehicle (e.g., Fc). See, 
e.g., International Publication No. WO 96/11953. The use of 
dextran conjugated to therapeutic or diagnostic immunoglo 
bulins has been reported. See, e.g., European Patent Publica 
tion No. 0315456, which is hereby incorporated by refer 
ence. The present invention also encompasses the use of 
dextran of about 1 kD to about 20 kD. 
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0201 In general, chemical modification can be performed 
under any suitable condition used to react a protein with an 
activated polymer molecule. Methods for preparing chemi 
cally modified polypeptides will generally comprise the steps 
of: (a) reacting the polypeptide with the activated polymer 
molecule (such as a reactive ester or aldehyde derivative of 
the polymer molecule) under conditions whereby a FGF21 
protein variant becomes attached to one or more polymer 
molecules, and (b) obtaining the reaction products. The opti 
mal reaction conditions will be determined based on known 
parameters and the desired result. For example, the larger the 
ratio of polymer molecules to protein, the greater the percent 
age of attached polymer molecule. In one embodiment of the 
present invention, chemically modified FGF21 mutants can 
have a single polymer molecule moiety at the amino-terminus 
(see, e.g., U.S. Pat. No. 5,234,784) 
0202 In another embodiment of the present invention, 
FGF21 protein variants can be chemically coupled to biotin. 
The biotin/FGF21 protein variants are then allowed to bind to 
avidin, resulting in tetravalent avidin/biotin/FGF21 protein 
variants. FGF21 protein variants can also be covalently 
coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and 
the resulting conjugates precipitated with anti-DNP or anti 
TNP-IgM to form decameric conjugates with a valency of 10. 
0203 Generally, conditions that can be alleviated or 
modulated by the administration of the present chemically 
modified FGF21 mutants include those described herein for 
FGF21 protein variants. However, the chemically modified 
FGF21 mutants disclosed herein can have additional activi 
ties, enhanced or reduced biological activity, or other charac 
teristics, such as increased or decreased half-life, as com 
pared to unmodified FGF21 mutants. 
0204 Therapeutic Compositions of FGF21 Mutants and 
Administration Thereof 
0205 Therapeutic compositions comprising FGF21 
mutants are within the scope of the present invention, and are 
specifically contemplated in light of the identification of sev 
eral mutant FGF21 sequences exhibiting enhanced proper 
ties. Such FGF21 mutant pharmaceutical compositions can 
comprise a therapeutically effective amount of an FGF21 
protein variant in admixture with a pharmaceutically or 
physiologically acceptable formulation agent selected for 
suitability with the mode of administration. 
0206. Acceptable formulation materials preferably are 
nontoxic to recipients at the dosages and concentrations 
employed. 
0207. The pharmaceutical composition can contain for 
mulation materials for modifying, maintaining, or preserv 
ing, for example, the pH, osmolarity, Viscosity, clarity, color, 
isotonicity, odor, Sterility, stability, rate of dissolution or 
release, adsorption, or penetration of the composition. Suit 
able formulation materials include, but are not limited to, 
amino acids (such as glycine, glutamine, asparagine, argin 
ine, or lysine), antimicrobials, antioxidants (such as ascorbic 
acid, Sodium sulfite, or sodium hydrogen-sulfite), buffers 
(such as borate, bicarbonate, Tris-HCl, citrates, phosphates, 
or other organic acids), bulking agents (such as mannitol or 
glycine), chelating agents (such as ethylenediamine tetraace 
tic acid (EDTA)), complexing agents (such as caffeine, poly 
vinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta 
cyclodextrin), fillers, monosaccharides, disaccharides, and 
other carbohydrates (such as glucose, mannose, or dextrins), 
proteins (such as serum albumin, gelatin, or immunoglobu 
lins), coloring, flavoring and diluting agents, emulsifying 
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agents, hydrophilic polymers (such as polyvinylpyrrolidone), 
low molecular weight polypeptides, salt-forming counterions 
(such as Sodium), preservatives (such as benzalkonium chlo 
ride, benzoic acid, salicylic acid, thimerosal, phenethyl alco 
hol, methylparaben, propylparaben, chlorhexidine, Sorbic 
acid, or hydrogen peroxide), solvents (such as glycerin, pro 
pylene glycol, or polyethylene glycol), Sugar alcohols (such 
as mannitol or Sorbitol), Suspending agents, Surfactants or 
wetting agents (such as pluronics; PEG, Sorbitan esters; 
polysorbates such as polysorbate 20 or polysorbate 80; triton; 
tromethamine; lecithin; cholesterol or tyloxapal), stability 
enhancing agents (such as Sucrose or Sorbitol), tonicity 
enhancing agents (such as alkali metal halides; preferably 
Sodium or potassium chloride; or mannitol Sorbitol), delivery 
vehicles, diluents, excipients and/or pharmaceutical adju 
vants (see, e.g., Remington's Pharmaceutical Sciences (18th 
Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), 
and Subsequent editions of the same, incorporated herein by 
reference for any purpose). 
0208. The optimal pharmaceutical composition will be 
determined by a skilled artisan depending upon, for example, 
the intended route of administration, delivery format, and 
desired dosage (see, e.g., Remington's Pharmaceutical Sci 
ences, Supra). Such compositions can influence the physical 
state, stability, rate of in vivo release, and rate of in vivo 
clearance of the FGF21 protein variant. 
0209. The primary vehicle or carrier in a pharmaceutical 
composition can be either aqueous or non-aqueous in nature. 
For example, a suitable vehicle or carrier for injection can be 
water, physiological saline Solution, or artificial cerebrospi 
nal fluid, possibly Supplemented with other materials com 
mon in compositions for parenteral administration. Neutral 
buffered saline or saline mixed with serum albumin are fur 
ther exemplary vehicles. Other exemplary pharmaceutical 
compositions comprise Tris buffer of about pH 7.0-8.5, or 
acetate buffer of about pH 4.0–5.5, which can further include 
sorbitol or a suitable substitute. In one embodiment of the 
present invention, FGF21 protein variant compositions can be 
prepared for storage by mixing the selected composition hav 
ing the desired degree of purity with optional formulation 
agents (Remington's Pharmaceutical Sciences, Supra) in the 
form of a lyophilized cake oranaqueous Solution. Further, the 
FGF21 protein variant product can be formulated as a lyo 
philizate using appropriate excipients such as Sucrose. 
0210. The FGF21 protein variant pharmaceutical compo 
sitions can be selected for parenteral delivery. Alternatively, 
the compositions can be selected for inhalation or for delivery 
through the digestive tract, such as orally. The preparation of 
Such pharmaceutically acceptable compositions is within the 
skill of the art. 
0211. The formulation components are present in concen 
trations that are acceptable to the site of administration. For 
example, buffers are used to maintain the composition at 
physiological pH or at a slightly lower pH, typically within a 
pH range of from about 5 to about 8. 
0212. When parenteral administration is contemplated, 
the therapeutic compositions for use in this invention can be 
in the form of a pyrogen-free, parenterally acceptable, aque 
ous solution comprising the desired FGF21 protein variant in 
a pharmaceutically acceptable vehicle. Aparticularly Suitable 
vehicle for parenteral injection is sterile distilled water in 
which an FGF21 protein variant is formulated as a sterile, 
isotonic solution, properly preserved. Yet another preparation 
can involve the formulation of the desired molecule with an 
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agent, such as injectable microspheres, bio-erodible particles, 
polymeric compounds (such as polylactic acid or polygly 
colic acid), beads, or liposomes, that provides for the con 
trolled or sustained release of the product which can then be 
delivered via a depot injection. Hyaluronic acid can also be 
used, and this can have the effect of promoting Sustained 
duration in the circulation. Other suitable means for the intro 
duction of the desired molecule include implantable drug 
delivery devices. 
0213. In one embodiment, a pharmaceutical composition 
can be formulated for inhalation. For example, an FGF21 
protein variant can be formulated as a dry powder for inhala 
tion. FGF21 protein variant inhalation solutions can also be 
formulated with a propellant for aerosol delivery. In yet 
another embodiment, solutions can be nebulized. Pulmonary 
administration is further described in International Publica 
tion No. WO94/20069, which describes the pulmonary deliv 
ery of chemically modified proteins. 
0214. It is also contemplated that certain formulations can 
be administered orally. In one embodiment of the present 
invention, FGF21 protein variants that are administered in 
this fashion can be formulated with or without those carriers 
customarily used in the compounding of Solid dosage forms 
Such as tablets and capsules. For example, a capsule can be 
designed to release the active portion of the formulation at the 
point in the gastrointestinal tract when bioavailability is 
maximized and pre-systemic degradation is minimized. 
Additional agents can be included to facilitate absorption of 
the FGF21 protein variant. Diluents, flavorings, low melting 
point waxes, vegetable oils, lubricants, Suspending agents, 
tablet disintegrating agents, and binders can also be 
employed. 
0215. Another pharmaceutical composition can involve an 
effective quantity of FGF21 protein variants in a mixture with 
non-toxic excipients that are Suitable for the manufacture of 
tablets. By dissolving the tablets in sterile water, or another 
appropriate vehicle, Solutions can be prepared in unit-dose 
form. Suitable excipients include, but are not limited to, inert 
diluents, such as calcium carbonate, Sodium carbonate or 
bicarbonate, lactose, or calcium phosphate; or binding 
agents. Such as starch, gelatin, or acacia, or lubricating agents 
Such as magnesium Stearate, Stearic acid, or talc. 
0216. Additional FGF21 protein variant pharmaceutical 
compositions will be evident to those skilled in the art, includ 
ing formulations involving FGF21 protein variants in Sus 
tained- or controlled-delivery formulations. Techniques for 
formulating a variety of other sustained- or controlled-deliv 
ery means, such as liposome carriers, bio-erodible micropar 
ticles or porous beads and depot injections, are also known to 
those skilled in the art (see, e.g., International Publication No. 
WO 93/15722, which describes the controlled release of 
porous polymeric microparticles for the delivery of pharma 
ceutical compositions, and Wischke & Schwendeman, 2008, 
Int. J. Pharm. 364; 298-327, and Freiberg & Zhu, 2004, Int. J. 
Pharm. 282: 1-18, which discuss microsphere/microparticle 
preparation and use). 
0217. Additional examples of sustained-release prepara 
tions include semipermeable polymer matrices in the form of 
shaped articles, e.g. films, or microcapsules. Sustained 
release matrices can include polyesters, hydrogels, polylac 
tides (U.S. Pat. No. 3,773.919 and European Patent No. 0.058 
481), copolymers of L-glutamic acid and gamma ethyl-L- 
glutamate (Sidman et al., 1983, Biopolymers 22: 547-56), 
poly(2-hydroxyethyl-methacrylate) (Langer et al., 1981, J. 
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Biomed. Mater. Res. 15: 167-277 and Langer, 1982, Chem. 
Tech. 12: 98-105), ethylene vinyl acetate (Langer et al., 
supra) or poly-D-3-hydroxybutyric acid (European Patent 
No. 0 133988). Sustained-release compositions can also 
include liposomes, which can be prepared by any of several 
methods known in the art. See, e.g., Epstein et al., 1985, Proc. 
Natl. Acad. Sci. U.S.A. 82: 3688-92; and European Patent 
Nos. 0.036 676, O 088 046, and 0 143 949. 
0218. The FGF21 protein variant pharmaceutical compo 
sition to be used for in vivo administration typically must be 
sterile. This can be accomplished by filtration through sterile 
filtration membranes. Where the composition is lyophilized, 
sterilization using this method can be conducted either prior 
to, or following, lyophilization and reconstitution. The com 
position for parenteral administration can be stored in lyo 
philized form or in a solution. In addition, parenteral compo 
sitions generally are placed into a container having a sterile 
access port, for example, an intravenous solution bag or vial 
having a stopper pierceable by a hypodermic injection needle. 
0219. Once the pharmaceutical composition has been for 
mulated, it can be stored in sterile vials as a solution, Suspen 
Sion, gel, emulsion, Solid, or as a dehydrated or lyophilized 
powder. Such formulations can be stored either in a ready-to 
use form or in a form (e.g., lyophilized) requiring reconstitu 
tion prior to administration. 
0220. In a specific embodiment, the present invention is 
directed to kits for producing a single-dose administration 
unit. The kits can each contain both a first container having a 
dried protein and a second container having an aqueous for 
mulation. Also included within the scope of this invention are 
kits containing single and multi-chambered pre-filled 
Syringes (e.g., liquid Syringes and lyosyringes). 
0221) The effective amount of an FGF21 protein variant 
pharmaceutical composition to be employed therapeutically 
will depend, for example, upon the therapeutic context and 
objectives. One skilled in the art will appreciate that the 
appropriate dosage levels for treatment will thus vary depend 
ing, in part, upon the molecule delivered, the indication for 
which the FGF21 protein variant is being used, the route of 
administration, and the size (body weight, body Surface, or 
organ size) and condition (the age and general health) of the 
patient. Accordingly, the clinician can titer the dosage and 
modify the route of administration to obtain the optimal 
therapeutic effect. A typical dosage can range from about 0.1 
ug/kg to up to about 100 mg/kg or more, depending on the 
factors mentioned above. In other embodiments, the dosage 
can range from 0.1 g/kg up to about 100 mg/kg, or 1 ug/kg 
up to about 100 mg/kg, or 5 g/kg, 10 ug/kg, 15 ug/kg, 20 
g/kg, 25 ug/kg. 30 g/kg, 35 Lig/kg, 40 ug/kg, 45 Lig/kg, 50 
g/kg, 55 g/kg, 60 g/kg, 65ug/kg, 70 g/kg, 75ug/kg, up to 
about 100 mg/kg. In yet other embodiments, the dosage can 
be 50 g/kg, 100 ug/kg, 150 ug/kg, 2001g/kg, 250 g/kg, 300 
ug/kg, 350 g/kg, 400 g/kg, 450 g/kg, 500 ug/kg, 550 
ug/kg, 600 g/kg, 650 g/kg, 700 g/kg, 750 ug/kg, 800 
ug/kg, 850 g/kg, 900 g/kg, 950 g/kg, 100 lug/kg, 200 
ug/kg, 300 g/kg, 400 g/kg, 500 g/kg, 600 ug/kg, 700 
ug/kg, 800 ug/kg, 900 g/kg, 1000 g/kg, 2000 ug/kg, 3000 
ug/kg, 4000 ug/kg, 5000 ug/kg, 6000 ug/kg, 7000 ug/kg, 8000 
ug/kg, 9000 ug/kg or 10 mg/kg. 
0222. The frequency of dosing will depend upon the phar 
macokinetic parameters of the FGF21 protein variant in the 
formulation being used. Typically, a clinician will administer 
the composition until a dosage is reached that achieves the 
desired effect. The composition can therefore be adminis 
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tered as a single dose, as two or more doses (which may or 
may not contain the same amount of the desired molecule) 
over time, or as a continuous infusion via an implantation 
device or catheter. Further refinement of the appropriate dos 
age is routinely made by those of ordinary skill in the art and 
is within the ambit of tasks routinely performed by them. 
Appropriate dosages can be ascertained through use of appro 
priate dose-response data. 
0223) The route of administration of the pharmaceutical 
composition is in accord with known methods, e.g., orally; 
through injection by intravenous, intraperitoneal, intracere 
bral (intraparenchymal), intracerebroventricular, intramus 
cular, intraocular, intraarterial, intraportal, or intralesional 
routes; by Sustained release systems (which may also be 
injected); or by implantation devices. Where desired, the 
compositions can be administered by bolus injection or con 
tinuously by infusion, or by implantation device. 
0224. Alternatively or additionally, the composition can 
be administered locally via implantation of a membrane, 
sponge, or other appropriate material onto which the desired 
molecule has been absorbed or encapsulated. Where an 
implantation device is used, the device can be implanted into 
any suitable tissue or organ, and delivery of the desired mol 
ecule can be via diffusion, timed-release bolus, or continuous 
administration. 
Therapeutic Uses of FGF21 Polypeptide Mutants 
0225 FGF21 protein variants can be used to treat, diag 
nose, ameliorate, or prevent a number of diseases, disorders, 
or conditions, including, but not limited to metabolic disor 
ders. In one embodiment, the metabolic disorder to be treated 
is diabetes, e.g., type 2 diabetes mellitus. In another embodi 
ment, the metabolic disorder is obesity. Other embodiments 
include metabolic conditions or disorders such as type 1 
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic 
steatohepatitis (NASH), insulin resistance, hyperinsuline 
mia, glucose intolerance, hyperglycemia, metabolic Syn 
drome, hypertension, cardiovascular disease, atherosclerosis, 
peripheral arterial disease, stroke, heart failure, coronary 
heart disease, kidney disease, diabetic complications, neur 
opathy, gastroparesis and other metabolic disorders. 
0226. In application, a disorder or condition Such as type 1 
or type 2 diabetes mellitus or obesity can be treated by admin 
istering an FGF21 protein variant as described herein to a 
patient in need thereof in the amount of a therapeutically 
effective dose. The administration can be performed as 
described herein, such as by IV injection, intraperitoneal 
injection, intramuscular injection, or orally in the form of a 
tablet or liquid formation. In most situations, a desired dosage 
can be determined by a clinician, as described herein, and can 
represent a therapeutically effective dose of the FGF21 
mutant polypeptide. It will be apparent to those of skill in the 
art that a therapeutically effective dose of FGF21 mutant 
polypeptide will depend, inter alia, upon the administration 
schedule, the unit dose of antigen administered, whether the 
nucleic acid molecule or polypeptide is administered in com 
bination with other therapeutic agents, the immune status and 
the health of the recipient. The term “therapeutically effective 
dose” as used herein, means that amount of FGF21 mutant 
polypeptide that elicits the biological or medicinal response 
in a tissue system, animal, or human being sought by a 
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researcher, medical doctor, or other clinician, which includes 
alleviation of the symptoms of the disease or disorder being 
treated. 
Pharmaceutical Compositions 
0227. The present invention also provides pharmaceutical 
compositions comprising one or more of the FGF21 variants 
or mutants described herein and a pharmaceutically accept 
able carrier. In some embodiments the pharmaceutical com 
positions are prepared as injectables, either as liquid solutions 
or Suspensions; solid forms suitable for Solution in, or Sus 
pension in, liquid vehicles prior to injection can also be pre 
pared. Liposomes are included within the definition of a 
pharmaceutically acceptable carrier. Pharmaceutically 
acceptable salts can also be present in the pharmaceutical 
composition, e.g., mineral acid salts such as hydrochlorides, 
hydrobromides, phosphates, sulfates, and the like; and the 
salts of organic acids such as acetates, propionates, mal 
onates, benzoates, and the like. A thorough discussion of 
pharmaceutically acceptable excipients is available in Rem 
ington: The Science and Practice of Pharmacy (1995) Alfonso 
Gennaro, Lippincott, Williams, & Wilkins. 
Fusion Proteins and FGF21-Derived Peptidic Compounds 
0228. In another embodiment, the FGF21 variants of the 
present invention can be made into a fusion protein orpeptidic 
compound derived from the FGF21 variants amino acid 
sequences. Such fusion proteins and peptidic compounds can 
be made using standard techniques known in the art. For 
example, peptidic compounds can be made by chemical Syn 
thesis using standard peptide synthesis techniques and then 
introduced into cells by a variety of means known in the art for 
introducing peptides into cells (e.g., liposome and the like). 
0229. The in vivo half-life of the fusion protein or peptidic 
compounds of the invention can be improved by making 
peptide modifications, such as the addition of N-linked gly 
cosylation sites into FGF21 variants, or conjugating FGF21 
variants to poly(ethylene glycol)(PEG, pegylation), e.g., via 
lysine-monopegylation or cysteine-monopegylation. Such 
techniques have proven to be beneficial in prolonging the 
half-life of therapeutic protein drugs. It is expected that pegy 
lation of the FGF21 variants of the invention may result in 
similar pharmaceutical advantages. 
0230. In addition, pegylation can be achieved in any part 
of a polypeptide of the invention by the introduction of a 
normatural amino acid. Certain normatural amino acids can 
be introduced by the technology described in Deiters et al., J 
Am Chem Soc 125:11782-11783, 2003; Wang and Schultz, 
Science 301:964-967, 2003: Wang et al., Science 292:498 
500, 2001; Zhanget al., Science 303:371-373, 2004 or in U.S. 
Pat. No. 7,083,970. Briefly, some of these expression systems 
involve site-directed mutagenesis to introduce a nonsense 
codon, Such as an amber TAG, into the open reading frame 
encoding a polypeptide of the invention. Such expression 
vectors are then introduced into a host that can utilize a tRNA 
specific for the introduced nonsense codon and charged with 
the normatural amino acid of choice. Particular normatural 
amino acids that are beneficial for purpose of conjugating 
moieties to the polypeptides of the invention include those 
with acetylene and azido side chains. The FGF21 variants 
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containing these novel amino acids can then be pegylated at 
these chosen sites in the protein. 
EXAMPLES 
Example 1 
Preparation and PEGylation of FGF21 Variant Pro 
teins 
0231 Expression constructs for FGF21 variants: The 
FGF21 variants were cloned into the modified E. coli expres 
sion vector plT30a, described by Achmuller et al. (2007) 
(Nature Methods 4:1037-1043), to generate in-frame fusions 
to a hexa-histidine tag followed by the N'-EDDIE tag at the 
N-terminus of FGF21 (aa 33-209). 
0232 Expression and purification of FGF21 variants: The 
pET30a-His-NP-EDDIE-FGF21 expression plasmid was 
transformed into E. coli BL21 Star (DE3) competent cells (Invitrogen). Overnight growth from a single colony of 
freshly transformed cells was carried out in 50 mL of Terrific 
Broth (TB) containing 50 lug/mL of kanamycin at 37°C. The 
pre-culture was transferred into 1 L of TB medium with 
kanamycin and cultured in baffled flasks at 37°C. with shak 
ing at 250 rpm. After 6 hour of culture, expression of FGF21 
was induced by the addition of IPTG at a final concentration 
of 1 mM, and the cultures were grown overnight at 37°C. The 
cells were then harvested and resuspended into 50 mL of 
ice-cold lysis buffer; 50 mM Tris-HCl, pH 8, 150 mM NaCl, 
1 mM EDTA, followed by lysis using a MicrofluidizerTM 
0233. Inclusion bodies (IBs) were precipitated by cen 
trifugation at 30,000xg for 1 hour at 4°C. The IBs were 
washed with 50 mM Tris-HCl, pH 8, 150 mM. NaCl and then 
dissolved into 30 mL of dissolving buffer; 10 mM Tris-HCl, 
pH8, 100mMNaHPO, 6 MGnHC1. The dissolved IBs were 
clarified by centrifugation at 30,000xg for 1 hour at 25°C. 
The IB solution was loaded onto a 5 mL column of Ni-NTA 
high performance resin (GE Healthcare) equilibrated with the 
dissolving buffer. Proteins bound to the resin were eluted by 
decreasing the pH to 4.5. The eluate was conditioned by 
adjusting pH and adding dithiothreitol (DTT) at a concentra 
tion of 20 mM. The conditioned eluate was slowly diluted into 
1 L of refolding buffer; 50 mM Tris-HCl, pH 8, 0.5 Margin 
ine, 20 mM DTT, followed by incubation for 2 days at 4°C. 
The diluted sample was concentrated and buffer-exchanged 
into 20 mM Tris-HCl, pH 9 using an ultrafiltration method. 
The concentrated sample was loaded onto a 10 mL column of 
Qsepharose fast flow resin (GE Healthcare) equilibrated with 
20 mM Tri-HCl (pH9). 
0234. After washing the resin with the equilibration 
buffer, proteins bound to the resin were eluted with 20 mM 
Tris-HCl, pH 9, 500 mM. NaCl. To remove the cleaved off 
His-N' fusion fragment and any uncleaved fusion protein 
from the refolded FGF21 protein, the eluate was loaded onto 
a 5 mL column of Ni-NTA high performance resin equili 
brated with 20 mM Tris, pH 8.0, 50 mM imidazole, and the 
flow-through fraction containing FGF21 was collected. To 
reduce endotoxin levels, the FGF21 fraction was treated with 
an EndoTrap HD resin (Hyglos) equilibrated with 10 mM 
Tris, pH 8,50 mM imidazole, 500 mM. NaCl, 1 mM CaCl. 
The low-endotoxin sample was dialyzed against PBS and 
then sterilized with a 0.22 um filter. The purified FGF21 
protein was Snap-frozen in liquid nitrogen and stored at -80° 
C. Protein concentration was determined by absorbance at 
280 nm using 93.62 M-1 cm-1 as the molar extinction coef 
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ficient for FGF21. Protein purity and integrity were deter 
mined by HPLC, SDS-PAGE and liquid chromatography 
mass spectrometry. 
0235 Cysteine PEGylation of FGF21 variants: hsEGF21 
(R154C) variants have tendency to dimerize via the engi 
neered cysteine; therefore, prior to PEGylation the protein 
solution (typically 5 mg/ml in Tris buffer) was mildly reduced 
with 5 mM mercaptoethylamine for 30 minutes on ice and 
immediately desalted in 20 mM Tris, pH 7. The freshly 
reduced protein (typically 3 mg/ml) was then immediately 
PEGylated with 1.5 equivalent of 40 kDa branched male 
imido-PEG reagent (NOF catalog #GL2-400MA from the 
Sunbright series) for 3 hours on ice. The PEGylated protein 
was finally purified by anion exchange chromatography 
(MonoO) with overall yields of about 25%. 
0236 N-terminal PEGylation of FGF21 variants: The 
final concentration of the FGF21 variant and the 40 kDa 
branched PEG reagent (NOF catalog #GL2-400AL3 from the 
Sunbright series; 3:1 molar ratio to FGF21) was 3-4 mg/mL 
and 9-12 mg/mL, respectively. The buffer was 50 mM sodium 
acetate, pH 6.0, 25 mM sodium chloride and 40 mM sodium 
cyanoborohydride. The reaction mixtures were tumbled gen 
tly at 4°C. for 44 hr and the reaction conversion was moni 
tored over several time points. Approximate conversion at 20 
hr was 50% and at 44 hr was 70%. 
Example 2 
Generation of human FGF21 Disulfide Variants 
0237 Cloning library: The vector pGAPZalphaA (Invit 
rogen, Carlsbad, Calif.) was modified by adding a 3-lacta 
mase expression cassette in the vector's unique BamHI site. 
The B-lactamase expression cassette was generated as 
described by Hribar, et al (2008) BioTechniques 44:477-84. 
The human FGF21 cDNA encoding amino acids 33 to 209 
was cloned into the modified pCAPZ alpha A vector after the 
glyceraldehyde-3-phosphate dehydrogenase (GAP) pro 
moter in frame with N-terminal sequences including an alpha 
mating factor Secretion signal sequence, a six histidine affin 
ity purification tag, and a Tobacco Etch Virus (TEV) protease 
recognition sequence. A library of hFGF21 constructs was 
generated with each construct having Cys 103 and Cys 121 
that are in the wild-type sequence as well as two wild-type 
amino acids that were mutated to cysteines. The library was 
made by generating PCR fragments of the hFGF21 amino 
acid 33-209 coding region with primers that encoded a cys 
teine in place of the wild-type amino acid. The PCR frag 
ments were designed so that they shared sixteen base pairs of 
identical sequence with each other or the linearized modified 
pGAPZalphaA vector so that they could be joined using the 
In-Fusion enzyme (Takara Bio Co USA). Each construct was 
sequence verified before it was used for yeast strain genera 
tion. 
0238 Generating yeast strains: The Pichia pastoris yeast 
strain SMD11 68H (Invitrogen) was modified by disrupting 
the YPS1 gene as described byYao etal (2009).J. Biotechnol. 
January 15: 139(2): 131-6. The modified strain (SMD1168H 
delta YPS1) had resistance to 300 lug/mL blasticidin. About 
5-10 ug of sequence verified plasmid DNA was digested with 
AVr II and was mixed with SMD11 68H delta YPS1 cells that 
were prepared according to Invitrogen's manual for 
pGAPZC.-A. The cells mixed with a linearized plasmid in a 
0.2 cm cuvette (Bio-Rad, Hercules, Calif.). The cuvette with 
the cells and linearized plasmid was incubated on ice for 5 
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mM The cuvette was pulsed using a Gene Pulser-II (Bio-Rad) 
with voltage set to 1.5 kV, the capacitor set to 25 LF, and the 
pulse controller set to 400 Ohms. 
0239 Immediately after the pulse, 1 mL of ice-cold 1 M 
sorbitol was added to the cuvette, and its contents were trans 
ferred to a sterile 15 mL tube. The tube was incubated at 30° 
C. without shaking for 2 h. The electroporated cells were 
spread onYPDS (1% yeast extract, 2% peptone, 2% dextrose, 
1M Sorbitol, and 2% agar) plates containing 100 g/mL Zeo 
cin (Zeo). The plates were incubated from 3-10 days at 30°C. 
until colonies formed. Twenty four colonies of each construct 
were picked and used to inoculate 1 mLYPD growth medium 
containing 100 ug/mL Zeocin in a 96-well deep-well plate. 
The plate was incubated overnight at 30° C. in a shaker 
(Sheldon Manufacturing, Cornelius, Oreg.) at 900 RPM. A 10 
uL aliquot of each culture was removed and diluted into 990 
uL of PBS (pH 7.4) in a 96-well deep-well plate. 
0240 For colorimetric determination of B-lactamase 
activity, 50 uL of 1:100 diluted culture was transferred into a 
96-well microtiter plate. Nitrocefin (1 mg; EMD Chemicals, 
Gibbstown, N.J.) was dissolved in 100 uL DMSO and diluted 
into 1.9 mL PBS to obtain a working solution of 1 mM. The 
nitrocefin working solution (50 uL) was added into each well 
for a final concentration of 500 uM. After the addition of 
nitrocefin, the plate was incubated at room temperature (RT) 
in the dark for 5 min. Absorbance at 492 nm was measured on 
a Spectramax Plus microtiter plate reader (Molecular 
Devices, Sunnyvale, Calif.) to determine the B-lactamase 
activity. Glycerol stocks of the two strains with the highest 
B-lactamase activity for each construct were made and stored 
at 80° C. 
0241 Small scale expression and purification of hFGF21 
disulfide variants: The hFGF21 disulfide variant glycerol 
stocks from the two strains with the highest B-lactamase 
specific activity for each construct were used to inoculate 1 
mL of Buffered Complex Glucose Medium (1% yeast extract, 
2% peptone, 100 mM potassium phosphate, pH 6.0, 1.34% 
YNB, 4x10-5% biotin, 2% glucose, and 2% casamino acids) 
in 96-well deep-well plates. The cultures were grown at 30° 
C. with shaking at 900 RPM (Sheldon Manufacturing, Cor 
nelius, Oreg.) for approximately 48 h until the cell growth 
reached Saturation. An aliquot of the Saturated culture (25ul) 
was used to inoculate 5 mL of Buffered Complex Glucose 
Medium in 24-well deep-well plates. The plates were incu 
bated overnight at 30°C. in a shaker (Sheldon Manufacturing, 
Cornelius, Oreg.) at 350 RPM. After about 24 h the plates 
were centrifuged at 2500xg for 15 min. The media was aspi 
rated off of the pelleted cells and added to an Amicon ultra-15 
centrifugal filter unit (Millipore, Billerica, Mass.) with a 10 
kDa cutoff membrane. Ten mL of PBS, pH 7.4 containing 10 
mM imidazole and 1x Halt EDTA-free protease inhibitor 
cocktail (Thermo, Rockford, Ill.) was added to the media in 
the concentrator to bring the total volume to 15 mL. 
0242. The filter unit was centrifuged at 4000 RMP in a 
Sorvall Legend RT plus centrifuge (Thermo) for 30 min The 
concentrator flow through was discarded and about 13 mL of 
PBS, pH 7.4 was added to the concentrated media. The filter 
unit was centrifuged again at 4000 RMP for 30 min. The 
concentrated buffer exchanged sample was loaded onto a 
nickel-nitrilotriacetic acid (Ni-NTA) spin column (Qiagen, 
Valencia, Calif.). The column was centrifuged at 270xg (1600 
rpm) in a Sorvall Legend Micro 21R centrifuge (Thermo) for 
5 min, and then washed two times with 600 uL of PBS, pH 7.4 
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containing 10 mM imidazole. The 6 HIS tagged hFGF21 
variants were eluted with 200 uI of PBS, pH 7.4 containing 
300 mM imidazole. 
0243 Medium scale expression and purification of 
hFGF21 disulfide variants: The hEGF21 disulfide variant 
glycerol stocks from the strains that expressed hFGF21 dis 
ulfide variants with the highest activity, when tested in the two 
point pFRK cellular assay (10 and 100 nM), were used to 
inoculate 5 mL of Buffered Complex Glucose Medium (1% 
yeast extract, 2% peptone, 100 mM potassium phosphate, pH 
6.0, 1.34% YNB, 4x10-5% biotin, 2% glucose, and 2% 
casamino acids) containing 100 ug/mL Zeocin in a 50 mL 
sterile tube. The cultures were grown at 30°C. with shaking 
at 250 RPM for approximately 48 h until the cell growth 
reached saturation. An aliquot of the saturated culture (50 uL) 
was used to inoculate 100 mL of Buffered Complex Glucose 
Medium in a 250 mL Ultra Yield flask (Thomson Instrument 
Co, Oceanside, Calif.). The flasks were incubated overnight 
at 30° C. in a shaker at 300 RPM. After about 24 h the cells 
were centrifuged at 2500xg for 15 min. The media (80 mL) 
was aspirated off of the pelleted cells and added to a Centri 
con-70 centrifugal filter unit (Millipore, Billerica, Mass.) 
with a 10 kDa cutoff membrane. The filter unit was centri 
fuged at 4000 RMP in a Sorvall Legend RT plus centrifuge 
(Thermo) for 30 mM The remaining clarified media (about 20 
mL) was added to a Centricon-70 centrifugal filter and the 
total volume in the filter was increased to 80 mL by adding 
PBS, pH7.4 containing 10 mM imidazole and 1xEDTA-free 
Halt protease inhibitor cocktail. The filter unit was centri 
fuged again at 4000 rpm for 30 mM. The Volume of the 
concentrated media in the filter unit was increased to 80 mL 
by adding PBS, pH 7.4 containing 10 mM. The filter unit was 
centrifuged again at 4000 rpm for 30 min. 
0244. The concentrated buffer exchanged sample was 
loaded onto a 1 mL His-Gravitrap column (GE Lifesciences, 
Piscataway, N.J.) that was pre-equilibrated with PBS, pH 7.4 
containing 10 mM imidazole. The column was washed with 
10 mL of PBS, pH 7.4 containing 20 mM imidazole. The 
6HIS tagged hFGF21 variants were eluted with 2.5 mL of 
PBS, pH 7.4 containing 300 mM imidazole. The 2.5 mL of 
elution buffer was applied to a 10 mL PD-10 desalting column 
that was pre-equilibrated with 25 mL of PBS, pH 7.4 contain 
ing 10 mM imidazole. The 6HIS tagged disulfide variants 
were eluted from the desalting column with 3.5 mL of PBS, 
pH 7.4 containing 10 mM imidazole. 
0245. The 6HIS tag was removed from the desalted affin 
ity-purified hFGF21 disulfide variants by adding ProTEV 
protease (250 units; Promega, Madison, Wis.) and incubating 
the sample at room temperature for 2 hand overnight at 4°C. 
The tag-cleaved hFGF21 disulfide variants loaded onto a 1 
mL His-Gravitrap column that was pre-equilibrated with 
PBS, pH 7.4 containing 10 mMimidazole. The flow-through 
containing the tag-cleaved hFGF21 disulfide variants was 
collected. The His-Gravitrap column was washed with 5 mL 
with PBS, pH 7.4 containing 10 mM imidazole. The column 
flow through was collected and added to the flow through 
from the tag cleavage reaction. The combined flow-through 
samples (about 8.5 mL) were concentrated to about 1 mL with 
Amicon ultra-15 centrifugal filter with a 10 kDa cutoff mem 
branes. The concentrated hEGF21 disulfide variants were 
frozen at -80° C. until being assayed in the pERK cellular 
assay. 
Example 3 
Measuring 2-Deoxyglucose (2-DOG) Uptake 
0246 More recently, FGF21 has been shown to stimulate 
glucose-uptake in mouse 3T3-L1 adipocytes in the presence 
US 2012/0129766 A1 
and absence of insulin, and to decrease fed and fasting blood 
glucose, triglycerides, and glucagon levels in ob?ob and db/db 
mice and 8 week old ZDF rats in a dose-dependent manner, 
thus, providing the basis for the use of FGF21 as a therapy for 
treating diabetes and obesity (see, e.g., patent publication 
WO03/011213, and Kharitonenkov et al., (2005) Jour. of 
Clinical Invest. 115:1627-1635). Also, FGF21 was observed 
to stimulate tyrosine phosphorylation of FGFR-1 and 
FGFR-2 in 3T3-L1 adipocytes. 
0247 T3-L1 fibroblasts were purchased from ATCC 
(Catalog #CL173). The cells were grown to confluency in 150 
cm petri-dish and were maintained in DMEM with high glu 
cose (Invitrogen #11995065) supplemented with 10% Fetal 
Bovine Serum and 1% penicillin-streptomycin for an addi 
tional 4 days. Cells were then differentiated in the above 
media Supplemented with 4 g/ml insulin (Sigma Catalog 
#1-5500), 115 g/ml IBMX (Sigma Catalog #15879) and 
0.0975ug/ml dexamethasone (Sigma Catalog #D1756) for 3 
days after which the differentiation media was replaced with 
complete DMEM. One plate of differentiated 3T3-L1 adipo 
cytes were seeded on four 96-well plates the day after 
medium replacement. 
0248. The adipocytes were then treated with FGF21-WT 
and FGF21 variants (see Table 2 for list of variants; 30 uM to 
100 nM is the typical concentration range used) overnight in 
complete medium. The adipocytes treated with FGF21 
samples are serum starved in 50 ul per well KRH buffer 
(0.75% Na Cl; 0.038%. KCl; 0.0196% CaC1; 0.032% 
Mg,504; 0.025M Hepes, pH 7.5: 0.5% BSA; 2 mM sodium 
pyruvate) for 2 hours. The wells for blank were added with 1 
ul (final concentration 5 g/ml) cytochalasin B for 15 min. 
3H]-2-DOG (20.6 mci/mmol. 1 mci/ml), which was diluted 
1:20 in 5.1 mM cold 2-DOG, 1 ul diluted 2-DOG per well was 
added to the cells and incubated for 5 min. The cells were 
washed with 100 ul/well KRH buffer three times. 40 ul/well 
1% SDS were added to cells and the cells were shaken for at 
least 10 min. 200 ul/well scintillation fluid were added and the 
plates were shaken overnight and read in beta-microplate 
reader. The values obtained from an entire column/row which 
were treated with cytochalasin B was averaged and subtracted 
from all other values. The data were analyzed by GraphPad 
prism software, the results of which are summarized in Table 
2. 
TABLE 2 
Summary of EC50 values and relative potencies (Fold-WT) of FGF21 
WT and FGF21 variants in the 3T3-L1 adipocyte 2-deoxy-glucose 
2-DOG) uptake assay. 
ECSO Fold-WT 
Variant ID Standardized name (nM) (1) N 
V5 hFGF21(33-209)-V5 3.3 1.5 1 
V7 hFGF21(33-209)-V7 3.9 1.8 1 
V8 hFGF21(33-209)-V8 1.8 O.8 1 
V9 hFGF21(33-209)-V9 3.1 1.O 1 
V10 hFGF21(33-209)-V10 2.8 1.3 1 
V11 hFGF21(33-209)-V11 3.4 1.6 1 
V12 hFGF21(33-209)-V12 3.2 1.5 1 
V13 hFGF21(33-209)-V13 2.9 1.3 1 
W14 hFGF21 (33-209)-V14-pool1 O.S6 1.O 7 
W14-N13 OD hFGF21 (33-209)-V14-pool2 O.6O 1.5 4 
W14-N-PEG hFGF21 (33-209)-V14pool1- 5.7 8.8 3 
N-40 kDa bPEG-AL 
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TABLE 2-continued 
Summary of EC50 values and relative potencies (Fold-WT) of FGF21 
WT and FGF21 variants in the 3T3-L1 adipocyte 2-deoxy-glucose 
2-DOG) uptake assay. 
ECSO Fold-WT 
Variant ID Standardized name (nM) (1) N 
V14-L174P. hFGF21(33-209)-V14-L174P, 4.3 8.9 6 
V15 hFGF21(33-209)-V15 3.2 1.5 
V16 hFGF21(33-209)-V16 3.1 1.4 
W18 hFGF21(33-209)-V18 2.6 O.8 
V53 hFGF21(33-209)-V53 O.78 1.4 3 
V54 hFGF21(33-209)-V54 2.5 1.1 
V55 hFGF21(33-209)-V55 3.7 1.7 
V56 hFGF21(33-209)-V56 3.0 1.3 
V57 hFGF21(33-209)-V57 O.60 O.69 4 
V58 hFGF21(33-209)-V58 O.31 1.1 
V59 hFGF21(33-209)-V59 0.67 O.69 3 
V61 hFGF21(33-209)-V61 1.9 O.9 
V62 hFGF21(33-209)-V62 1.5 0.7 
V63 hFGF21(33-209)-V63 1.9 O.9 
V73 hFGF21(33-209)-V73 1.1 2.8 2 
V73-N-PEG hFGF21(33-209)-V73-N-40 O.89 1.8 2 
kDa bREG-AL 
V76 hFGF21(33-209)-V76 0.77 1.O 
V76-154C-PEG hFGF21(33-209)-V76-154C- 1.8 4.5 2 
40kDa bPEG-MA 
V79 hFGF21(33-209)-V79 2.3 2.3 
V82 hFGF21(33-209)-V82 10 2.0 
V83 hFGF21(33-209)-V83 7.4 1.5 
W84 hFGF21(33-209)-V84 1.6 2.8 3 
V85 hFGF21(33-209)-V85 1.1 1.5 
WT hFGF21(33-209)-WT-CH O.99 1.O 2O 
WT-L174P hFGF21(33-209)-WT-AM 2.2 1.5 3 
WTN-PEG hFGF21(33-209)-WT-N-40 1.1 3.1 2 
kDa bREG-AL 
WT-R154C-PEG hFGF21(33-209)-WT. 1.4 3.3 2 
R154C-40 kDa bPEG-MA 
(1) “Fold-WT is ratio of EC50 value of the FGF21 variant to FGF21-WT carried out “head 
to head” in the same experiment, 
Example 4 
pERK In Cell Western (ICW) Assay 
0249 HEK293 cells stably transfected with human 
B-klotho were cultured in DMEM high glucose, 10% FBS, 
1% PS and 600 ng/ml G418 are seeded in poly-D-lysine 
coated 96-well plates (BD bioscience, 356640) at 30,000 
cells per well overnight. The cells were serum starved in 
DMEM high glucose, 0.5% BSA and 10 mM HEPES for 4 
hours. WTFGF21 and the FGF21 variants (see Table 3 for list 
of variants) were diluted to various concentrations (100 pM to 
300 nM is the typical concentration range used) in starvation 
medium. The cells were stimulated with FGF21 for 10 min. 
Following FGF21 stimulation, the media was aspirated from 
the wells and the cells were washed once with 100 ul cold 
PBS and then fixed with 100 ul of 4% formaldehyde for 15 
mins at RT and followed by an additional 10 mins incubation 
with 100 ul ice-cold methanol. 
(0250. After fixation, the cells were washed with 0.3% 
TritonX-100 in PBS four times, 5 mins each. 150 ul Odyssey 
Blocking Buffer was added to the permeabilized cells at room 
temperature for 1.5 hours. Phospho-ERK (pERK) antibody 
was diluted to a concentration of 0.17 g/ml (1:200 dilution, 
US 2012/0129766 A1 
or the dilutions indicated), and total-ERK (tRK) antibody 
was diluted to a concentration of 2.2 Lug/ml (1:200 dilution, or 
the dilutions indicated) in Odyssey Blocking Buffer. 50 ul 
was added to every well, omitting one column which was only 
treated with secondary antibody to normalize for back 
ground. The plate was covered with the wet paper tower and 
lid to prevent evaporation and then incubated at 4°C. over 
night. 
0251. Afterwards, the primary antibody was aspirated and 
the cells were washed four times with 0.3% Tween 20 in PBS 
for 5 mins each. During the washing, the secondary antibody 
reaction mixture was prepared in Odyssey Blocking Buffer 
containing 1:1000-diluted (or the dilutions indicated) goat 
anti-mouse Alexa 680 and 1:1000-diluted (or the dilutions 
indicated) IRDye800 goat anti-rabbit antibody. Once the 
washing was completed, 40 ul of the reaction mixture was 
added to each well. Plates were covered with black lid to 
protect the secondary antibody from light, and plates were 
incubated at RT for 1 hr on a shaker. Finally, the cells were 
washed again four times with 0.3% Tween 20 in PBS for 5 
min each and then scanned on the LI-COR Bioscience Odys 
sey Infrared Imaging System (Li-Cor BioSciences, Lincoln, 
Nebr.) in the 700 nm (red) and 800 nm (green) channels. 
Alexa 680 stained the tRRK with far-red fluorescence (emis 
sion wavelength 668 nm), while IRDye800 stained the pleRK 
with green fluorescence (emission wavelength 800 nm). To 
eliminate the fluorescent background, the values obtained 
from an entire column/row which was treated with only sec 
ondary antibody was averaged and subtracted from all other 
values obtained from the plate. For normalization of the 
amount of pH.RK present in each sample, the values for pERK 
in each well was divided by the values oftERK. The data were 
analyzed by GraphPad prism software, the results of which 
are summarized in Table 3. 
TABLE 3 
Summary of EC50 values and relative potencies (Fold-WT) of FGF21 
WT and FGF21 variants in the pERK cellular assay using HEK293 
cells stably transfected with human B-klotho. 
Fold 
EC50 WT 
Variant ID Standardized Name (nM) (1) N 
V5 hFGF21(33-209)-V5 26 9.3 1 
V7 hFGF21(33-209)-V7 19 6.8 1 
V8 hFGF21(33-209)-V8 14 S.O. 1 
V9 hFGF21(33-209)-V9 13 2.4 1 
V10 hFGF21(33-209)-V10 18 3.3 1 
V11 hFGF21(33-209)-V11 28 18 1 
V12 hFGF21(33-209)-V12 14 S.O. 1 
V13 hFGF21(33-209)-V13 11 4.O. 1 
W14 hFGF21 (33-209)-V14-pool1 6.7 1.4 6 
V14-N130D hFGF21 (33-209)-V14-pool2 5.3 1.4 3 
V14-N-PEG hFGF21 (33-209)-V14pool 1-N-40 107 22 5 
kDa bREG-AL 
V14-R154C, hFGF21(33-209)-V14-R154C, L174P 6.7 1.O 3 
L174P 
V15 hFGF21(33-209)-V15 3.3 12 1 
V16 hFGF21(33-209)-V16 11 6.S 1 
W18 hFGF21(33-209)-V18 15 2.7 1 
V52 hFGF21(33-209)-V52 66 94 1 
V53 hFGF21(33-209)-V53 4.2 1.3 3 
V54 hFGF21(33-209)-V54 25 9.2 1 
V55 hFGF21(33-209)-V55 34 13 1 
V56 hFGF21(33-209)-V56 37 14 1 
V57 hFGF21(33-209)-V57 22 S4 3 
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TABLE 3-continued 
Summary of EC50 values and relative potencies (Fold-WT) of FGF21 
WT and FGF21 variants in the pERK cellular assay using HEK293 
cells stably transfected with human B-klotho. 
Fold 
EC50 WT 
Variant ID Standardized Name (nM) (1) N 
V58 hFGF21(33-209)-V58 3.6 2.6 1 
V59 hFGF21(33-209)-V59 6.5 1.6 3 
W60 hFGF21(33-209)-V60 7.6 2.2 1 
V61 hFGF21(33-209)-V61 22 6.3 1 
V62 hFGF21(33-209)-V62 24 6.8 1 
V63 hFGF21(33-209)-V63 13 3.7 1 
W64 hFGF21(33-209)-V64 2.9 O.80 1 
V73 hFGF21(33-209)-V73 5.8 1.7 3 
V73-N-PEG hFGF21(33-209)-V73-N-40 kDa 191 66 2 
bPEG-AL 
V76 hFGF21(33-209)-V76 3.4 O.47 3 
V76-154C- hFGF21(33-209)-V76-154C-40 8.3 2.4 4 
PEG kDa-bPEG-MA 
V79 hFGF21(33-209)-V79 2.2 O40 1 
V8O hFGF21(33-209)-V80 2.2 O40 1 
V81 hFGF21(33-209)-V81 11 2.1 1 
V82 hFGF21(33-209)-V82 1.5 2.7 1 
V83 hFGF21(33-209)-V83 O.21 O.38 1 
W84 hFGF21(33-209)-V84 4.5 1.1 3 
V85 hFGF21(33-209)-V85 2.0 O.30 1 
W86 hFGF21(33-209)-V86 8.5 4.5 1 
V87 hFGF21(33-209)-V87 1.9 1.6 1 
WT hFGF21(33-209)-WT-CH 7.4 1.O 33 
WT-R154C hFGF21(33-209)-WT-R154C 4.2 1.3 3 
WT-R154C- hFGF21(33-209)-WT-R154C-40 9.0 2.9 3 
PEG kDa bREG-MA 
WT-N-PEG hFGF21(33-209)-WT-N-40 2O 6.3 3 
kDa bREG-AL 
WT-L174P hFGF21(33-209)-WTAM 5.7 1.5 3 
(1) “Fold-WT is ratio of the EC50 value of the FGF21 variant to the EC50 value of 
FGF21-WT carried out “head to head” in the same experiment, 
Example 5 
In Vivo Tests of FGF21 and FGF21 Variants Phar 
macodynamics and Plasma Exposures 
0252. The ob?ob mouse is a mouse model for type 2 dia 
betes. The mice lack functional leptin and are characterized 
by hyperglycemia, insulin resistance, hyerphagia, hepatic Ste 
atosis and obesity. Male ob?ob mice (10-13 weeks old) were 
used to measure the effect on blood glucose of the following: 
(1) wildtype FGF21, (2) FGF21 variants, (3) PEGylated wild 
type FGF21, and (4) PEGylated FGF21 variants. 
0253) The wild type FGF21, variant FGF21 or PBS 
vehicle were administered s.c. at 1 mg/kg and 4 ml/kg once 
daily for 5 days. On the first day of the study, tail blood 
glucose and body weight were measured and mice were allo 
cated into different groups (n=8 pergroup) with mean glucose 
and body weight matched among the groups. Blood glucose 
was measured using a glucometer (OneTouch) on days 1, 3 
and 5 before dosing and 2 and 4 hours after dosing. The results 
of these studies are summarized in Table 4. 
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TABLE 4 
Percent reduction of total glucose AUC by FGF21 variants 
during 5-day screening studies in oblob nice. 
Glucose Glucose Fold 
AUC Fold AUC change 
Dose reduction change Dose reduction over WT 
Variant ID (mg/kg) vs. vehicle over WT Variant ID (mg/kg) vs. Vehicle (1) 
V mg/kg -30% 0.86 V57 mg/kg -18% O.90 
V5 mg/kg -25% 1.19 VS8 mg/kg -20% O.65 
V7 mg/kg -25% 1.19 VS9 mg/kg -2.2% O.69 
V8 mg/kg -1.6% O.76 V60 mg/kg -21% 1.OS 
V9 mg/kg -20% O.95 V61 mg/kg -5% O.25 
V10 mg/kg -31% 1.48 V62 mg/kg -2% O.10 
V11 mg/kg -29% O.83 V63 mg/kg -1.3% O.65 
V12 mg/kg -31% 0.89 V73 mg/kg -2.6% O.74 
V13 mg/kg -2.7% 0.87 V76 exp1 mg/kg -30% O.86 
V14 exp1 mg/kg -3.3% 0.94 V76 exp2 mg/kg -1.6% 1.45 
V14 exp2 mg/kg -37% 1.06 W79 mg/kg -30% 1.15 
V14 exp3 mg/kg -36% 1.16 V8O mg/kg, -23% O.88 
V14-R154C, mg/kg -30% O.97 V81 mg/kg -24% O.92 
L174P 
V15 mg/kg -2.6% O.74 V82 mg/kg -31% 1.19 
V16 mg/kg -24% 0.69 V83 exp1 mg/kg -3.2% 1.23 
W18 mg/kg -20% 0.95 V83 exp2 mg/kg -30% 2.73 
V53 mg/kg -3.2% 1.03 V84 mg/kg, -23% O.88 
V54 mg/kg -25% 0.78 V85 mg/kg -1.6% 1.45 
V55 mg/kg -2.2% O.69 WT-L174P mg/kg -28% O.92 
V56 mg/kg -20% 0.63 WT mg/kg -2.7% 1.O 
(n = 9) 
(1) “Fold change over WT is the ratio of the “Glucose AUC reduction” of the FGF21 variant to the “Glucose AUC 
reduction” of FGF21-WT carried out “head to head” in the same experiment, 
0254 Mice were administered s.c. with PEGylated 
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and 4 hours after dosing. Additional blood glucose measure 
FGF21 wild type at 1 mg/kg, PEGylated FGF21 variants at 
0.3, 1 or 3 mg/kg, or PBS vehicle at 4 ml/kg at 2 times a week 
for 2 weeks. On the first day of the study, tail blood glucose 
and body weight were measured and mice were allocated into 
different groups (n=8 per group) with mean glucose and body 
weight matched among the groups. Blood glucose was mea 
Sured using a glucometer on days 1, 4, 8 and 11 before dosing 
ments were taken at 24 hours post each dose, on days 2, 5, 9 
and 12. Plasma insulin was measured on day 1 before dosing 
and day 12, 24 hours post the last dose. Plasma triglycerides 
were measured on day 1 before dosing and day 5, 24 hours 
post the second dose. The results of these studies are Summa 
rized in Table 5. 
TABLE 5 
% changes versus vehicle in plasma glucose, insulin, triglyceride 
(TG), body weight (BW) gain, liver TG/lipid by PEGylated FGF21 
wild type (WT) and variants during 12-day studies in ob/ob nice. 
Variant ID 
WT-N-PEG, 
exp3 
Dose Total Glucose Plasma Liver TG Plasma TG 
(mg/kg) AUC Insulin BW gain (or lipid) (day 5) 
O -8% -24% -4% -19% -48% 
(lipid) 
O -24% -45% -1% -3% -35% 
O -30% -40% -5% -1.8% -59% 
(lipid) 
O.3 +2% -1.7% +1% +7% -29% 
O +1% -39% -1% +6% -40% 
3.0 -1.1% -39% O% +7% -24% 
O.3 -8% -6% O% -19% -24% 
O -4% -49% -2% -4% -43% 
3.0 -1.7% -48% -3% -3.3% -44% 
O -8% +21% +1% -5% -1.7% 
O -28% -14% -1% -7% -53% 
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TABLE 5-continued 
% changes versus vehicle in plasma glucose, insulin, triglyceride 
(TG), body weight (BW) gain, liver TG/lipid by PEGylated FGF21 
May 24, 2012 
wild type (WT) and variants during 12-day studies in ob/ob nice. 
Dose Total Glucose Plasma Liver TG 
Variant ID (mg/kg) AUC Insulin BW gain (or lipid) 
V73-N-PEG O.3 -1% --29% +2% +1% 
V73-N-PEG 1.O O% +24% +2% -1% 
V73-N-PEG 3.0 -1.6% --8% +3% --8% 
V76-154C-PEG O.3 -20% +22% O% -3% 
V76-154C-PEG 1.O -20% -21% -1% -25% 
V76-154C-PEG 3.0 -31% -38% -5% -40% 
0255. The V76-154C-PEG variant exhibits an excellent in 
vivo metabolic profile, as seen in Table 5. V76-154C-PEG 
also exhibits excellent liver triglyceride lowering properties 
(-25% liver triglyceride change, significantly different from 
the vehicle control group; FIG. 1) compared with FGF21 
WT-R154C-PEG (-7% Liver Triglyceride change, not sig 
nificantly different from the vehicle control group; FIG. 1). 
When both were dosed at 1 mg/kg in the same study (WT 
R154C-PEG, exp3), the plasma exposures (FIG. 2) for both 
compounds were equivalent and other efficacy endpoints (To 
tal Glucose AUC, plasma insulin, body weight gain, and 
plasma triglycerides) were not significantly different. 
Example 6 
Plasma Stability Assay with Wild Type FGF21 and 
PEGylated FGF21 Variants 
0256 To determine the plasma stability of wild type 
FGF21 (FGF21-WT) in comparison to PEGylated FGF21 
variants, a plasma stability assay was implemented. Ten (10) 
ml of FGF21-WT (4.84 mg/ml) and 35.5 ul of FGF21-V76 
154C-PEG (2.12 mg/ml) were added to 90 ml and 264.5 ml of 
ob/ob mouse plasma (90% and 88% plasma). Each sample 
was made in 5 aliquots and incubated for 1 hr, 4 hr, 24 hr, 48 
hrand 72 hr. Plasma-treated samples were stored at 4°C. until 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS: 49 
<21 Oc 
<211 
<212> 
<213> 
SEO ID NO 1 
LENGTH: 209 
TYPE PRT 
ORGANISM: Homo sapiens 
<4 OOs SEQUENCE: 1 
Plasma TG 
(day 5) 
+24% 
+7% 
-22% 
-24% 
-45% 
-51% 
samples from all the time points were collected. Nine (9) ul of 
plasma-treated FGF21-WT and 27 Jul of plasma-treated 
FGF21-V76-154C-PEG were added to 750 n1 of medium 
(300 nM FGF21-WT with 1.2% plasma and 450 nM FGF21 
V76-154C-PEG with 3.6% plasma) and serially diluted 1:3 in 
media 8 times. HEK293 cells, stably transfected with human 
B-klotho, were treated with proteins for 10 min followed by 
standard protocols of pERK ICW. Untreated FGF21-WT, 
FGF21-V76-154C-PEG and 1.2% and 3.6% mouse plasma 
are also included as controls. The results of these experiments 
are graphically depicted by FIGS. 3A and 3B. 
(0257. While FGF21-WT lost activity over a short time 
frame (1-4 hours) when incubated with mouse plasma at 37° 
C., V76-154C-PEG by contrast retained its full activity for at 
least 72 hours when incubated with mouse plasma at 37° C. 
0258 While the present invention has been described with 
reference to the specific embodiments thereof, it should be 
understood by those skilled in the art that various changes 
may be made and equivalents may be substituted without 
departing from the true spirit and scope of the invention. In 
addition, many modifications may be made to adapt a par 
ticular situation, material, composition of matter, process, 
process step or steps, to the objective, spirit and scope of the 
present invention. All such modifications are intended to be 
within the scope of the present invention. 
Met Asp Ser Asp Glu Thr 
1. 5 
Val Lieu Ala Gly Lieu. Lieu. 
2O 
Asp Ser Ser Pro Lieu. Lieu. 
35 
Lieu. Tyr Thr Asp Asp Ala 
SO 
Gly 
Luell 
Glin 
Glin 
55 
Phe Glu 
Gly Ala 
25 
Phe Gly 
4 O 
Gn. Thir 
His 
1O 
Cys 
Gly 
Glu 
Ser 
Glin 
Glin 
Ala 
Gly Lieu. 
Ala His 
Val Arg 
45 
His Lieu. 
60 
Wall 
15 
Trp Ser 
Pro Ile Pro 
3 O 
Glin Arg 
Glu Ile Arg 
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- Continued 
Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
65 70 7s 8O 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
85 90 95 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu. Tyr Gly 
1OO 105 11 O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
115 12 O 125 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
13 O 135 14 O 
His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Pro Arg Gly 
145 150 155 160 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
1.65 17O 17s 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
18O 185 19 O 
Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
195 2OO 2O5 
Ser 
<210s, SEQ ID NO 2 
&211s LENGTH: 630 
&212s. TYPE: DNA 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 2 
atggacticgg acgaga.ccgg gttcgagcac toaggactgt gggtttctgt gctggctggit 6 O 
cittctgctgg gagcct gcca ggcacacc cc atc cc to act c cagt cct ct c ctdcaattic 12 O 
gggggg caag ticcggcagcg gtacct ctac acagatgatg CCC agcagac agaagcc cac 18O 
Ctggagat.ca gggaggatgg gacggtggggggggotgctg accagagc.cc caaagttctic 24 O 
Ctgcagctga aag ccttgaa gCCgggagtt attcaaatct tdgagt cala gaCat CC agg 3OO 
titcCtgtgcc agcggccaga tigggg.ccctg. tatggat.cgc. tcc actittga CCCtgaggcc 360 
tgcagct tcc gggagctgct tcttgaggac ggatacaatgtttaccagtic Caagcc cac 42O 
ggcctic cc.gc tigcacctgcc agggaacaag tocccacacc gggaccctgc accc.cgagga 48O 
c cagct cqct tcc togccact accaggcc tig ccc.ccc.gcac toccggagcc acccggaatc 54 O 
Ctggcc cc cc agc.ccc.ccga tigtgggct Co. tcggaccctic tagcatggit gggacct tcc 6OO 
Cagggc.cgaa gcc.ccagcta cqctt Cotga 63 O 
<210s, SEQ ID NO 3 
&211s LENGTH: 181 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 3 
His Pro Ile Pro Asp Ser Ser Pro Leu Lieu. Glin Phe Gly Gly Glin Val 
1. 5 1O 15 
Arg Glin Arg Tyr Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His 
2O 25 3O 
Lieu. Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser 
35 4 O 45 
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Pro Glu Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin 
SO 55 6 O 
Ile Lieu. Gly Val Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly 
65 70 7s 8O 
Ala Lieu. Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg 
85 90 95 
Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His 
1OO 105 11 O 
Gly Lieu Pro Lieu. His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro 
115 12 O 125 
Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Lieu Pro Pro 
13 O 135 14 O 
Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val 
145 150 155 160 
Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser 
1.65 17O 17s 
Pro Ser Tyr Ala Ser 
18O 
<210s, SEQ ID NO 4 
&211s LENGTH: 15 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Linker 
<4 OOs, SEQUENCE: 4 
ggggsggggs ggggs 15 
<210s, SEQ ID NO 5 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 5 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Ala Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Gly Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu Val Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly His Llys Ser Pro His Arg Asp Pro Ala Pro Arg Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Glu Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
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Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Thr 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 6 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 6 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Asn Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Ala Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Asn Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu Val Lieu. 
85 90 95 
Glu Asp Gly Tyr ASn Val Tyr Glin Ser Glu Ala His Gly Lieu. Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Glin Llys Ser Pro His Arg Asp Pro Ala Pro Arg Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Asn Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Thr 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 7 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OO > SEQUENCE: 7 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Asp Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys Ala Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
US 2012/0129766 A1 May 24, 2012 
36 
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1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 8 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 8 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Asp Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Glin Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 9 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 9 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
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Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys Ala Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 10 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
< 4 OO > SEQUENCE: 10 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Glin Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 11 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 11 
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Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Asp Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys Ala Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 12 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 12 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys Ala Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
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Ser 
<210s, SEQ ID NO 13 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 13 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Asp Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu. Pro Gly ASn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 14 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 14 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Asp Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Glin Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
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115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 15 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 15 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Asp Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys Ala Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 16 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 16 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
US 2012/0129766 A1 May 24, 2012 
41 
- Continued 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 17 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 17 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Leu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 18 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 18 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
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Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Glin Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 19 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 19 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys Ala Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
US 2012/0129766 A1 May 24, 2012 
43 
- Continued 
<210s, SEQ ID NO 2 O 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 2O 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ser His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Leu Pro Leu Pro Gly Lieu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 21 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 21 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ser His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Glin Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
US 2012/0129766 A1 
Pro 
145 
Pro 
Ser 
13 O 135 
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- Continued 
14 O 
Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser 
150 155 
Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr 
1.65 
<210s, SEQ ID NO 22 
&211s LENGTH: 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 
Asp Ser Ser Pro 
1. 
Lell 
Glu 
Lell 
Lys 
65 
Ser 
Glu 
His 
Pro 
Pro 
145 
Pro 
Ser 
Tyr 
Asp 
Glin 
SO 
Ala 
Luell 
Asn 
Luell 
Ala 
13 O 
Pro 
Luell 
Thir 
Gly 
35 
Luell 
Ser 
His 
Gly 
Pro 
115 
Arg 
Gly 
Ala 
Asp 
2O 
Thir 
Arg 
Phe 
Tyr 
Gly 
Phe 
Ile 
Met 
177 
Homo sapiens 
22 
Lieu. Lieu. Glin Phe 
5 
Asp Ala Glin Glin 
Val Gly Gly Ala 
4 O 
Ala Lieu Lys Pro 
55 
Phe Lieu. Cys Glin 
70 
Asp Pro Glu Ala 
85 
Asn Val Tyr Glin 
Asn Arg Ser Pro 
12 O 
Leul Pro Leu Pro 
135 
Lieu Ala Pro Glin 
150 
Val Gly Pro Ser 
1.65 
<210s, SEQ ID NO 23 
&211s LENGTH: 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 
Asp Ser Ser Pro 
1. 
Lell 
Glu 
Lell 
Glin 
65 
Tyr 
Asp 
Glin 
SO 
Thir 
Thir 
Gly 
35 
Luell 
Ser 
Asp 
2O 
Thir 
Lys 
Arg 
177 
Homo sapiens 
23 
Lieu. Lieu. Glin Phe 
5 
Asp Asp Glin Glin 
Val Gly Gly Ala 
4 O 
Ala Lieu Lys Pro 
55 
Phe Lieu. Cys Glin 
70 
Gly 
Thir 
25 
Ala 
Gly 
Ser 
105 
His 
Gly 
Pro 
Glin 
Gly 
Thir 
25 
Ala 
Gly 
17O 
Gly 
Glu 
His 
Wall 
Pro 
Ser 
90 
Glu 
Arg 
Luell 
Pro 
Gly 
17O 
Gly 
Glu 
His 
Wall 
Pro 
Glin 
Ser 
Glin 
Ile 
Asp 
Phe 
Ala 
Asp 
Pro 
Asp 
155 
Arg 
Glin 
Ala 
Glin 
Ile 
Asp 
7s 
Val Arg 
His Lieu. 
Ser Pro 
45 
Glin Ile 
6 O 
Gly Ala 
Arg Glu 
His Gly 
Pro Ala 
125 
Pro Ala 
14 O 
Val Gly 
Ser Pro 
Val Arg 
His Lieu. 
Ser Pro 
45 
Glin Ile 
6 O 
Gly Ala 
Glin 
Glu 
Glu 
Lel 
Lel 
Lel 
Lel 
11 O 
Lel 
Ser 
Ser 
Glin 
Glu 
Glu 
Luell 
Luell 
17s 
Arg 
15 
Ile 
Ser 
Gly 
Luell 
95 
Pro 
Glin 
Pro 
Ser 
Tyr 
17s 
Arg 
15 
Ile 
Ser 
Gly 
Asp 
160 
Ala 
Arg 
Luell 
Wall 
Gly 
Luell 
Luell 
Gly 
Glu 
Asp 
160 
Ala 
Arg 
Luell 
Wall 
Gly 
8O 
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Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 24 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 24 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Glin Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 25 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 25 
Asp Ser Ser Pro Lieu Val Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
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Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Ser Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ser Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 26 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 26 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 27 
&211s LENGTH: 177 
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212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 27 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys. Thir Ser Arg Phe Lieu. Cys Gln Llys Pro Asp Gly Thr Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 28 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 28 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Ala Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
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145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 29 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 29 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys Ala Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 3 O 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 30 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys Ala Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
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Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 31 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 31 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Thr Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 32 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 32 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
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Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 33 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 33 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Thr Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser Arg Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 34 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
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<4 OOs, SEQUENCE: 34 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Ala Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asn Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser Arg Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 35 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 35 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Cys Asn Llys Ser Pro His Arg Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
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1.65 17O 17s 
Ser 
<210s, SEQ ID NO 36 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 36 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser Arg Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 37 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OO > SEQUENCE: 37 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Thr Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asin Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
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His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser Arg Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Pro Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 38 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 38 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Glu Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Arg Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 39 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 39 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
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Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Leu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 4 O 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 4 O 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Leu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 41 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 41 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
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1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys. Thir Ser Arg Phe Lieu. Cys Gln Llys Pro Asp Gly Thr Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Leu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 42 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 42 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
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<210s, SEQ ID NO 43 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 43 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys. Thir Ser Arg Phe Lieu. Cys Gln Llys Pro Asp Gly Thr Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Ser Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 44 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 44 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Lys. Thir Ser Arg Phe Lieu. Cys Gln Llys Pro Asp Gly Thr Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Ser Arg Gly 
115 12 O 125 
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Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 45 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 45 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Thr Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Thir His Gly Lieu Pro Leu 
1OO 105 11 O 
His Lieu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Ser Arg Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Ala Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 46 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 46 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
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Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Glu Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Leu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 47 
&211s LENGTH: 546 
&212s. TYPE: DNA 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 47 
Caccc.cat co Ctgacticcag ticct Ctcct caatt.cgggg gccaagt ccg gcagcgg tac 6 O 
Ctct acacag atgatgcc.ca gcagacagaa goccacctgg agat Caggga ggatgggacg 12 O 
gtgggggg.cg Ctgctgacca gagcc.ccgala agt ct cotgc agctgaaagc Cttgaag.ccg 18O 
ggagittatt c aaatcttggg agt caagaca toc aggttcc titgc.ca.gcg gcc agatggg 24 O 
gccCtgtatg gat.cgcticca Ctttgaccct gaggcctgca gct tccggga gctgctt Ctt 3OO 
gaggacggat acaatgttta C cagt ccgala gcc cacggcc ticcc.gctgca CctgcCaggg 360 
aacaagtic cc cacaccggga ccctgcaccc cdaggaccag citcqct tcct gcc actacca 42O 
ggcctgcc cc cc.gcactic cc ggagccaccc ggaatcc tig C cc cc cagcc ccc.cgatgtg 48O 
ggct cotcgg accctctgag catggtggga cct tccCagg gcc.gaag.ccc cagctacgct 54 O 
t cct ga 546 
<210s, SEQ ID NO 48 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 48 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glin Lieu. Arg Ala Lieu. Arg Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Arg Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
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1OO 105 
Ala 
125 
Pro His Pro 
12 O 
Pro Ser 
115 
His Lieu. Gly Asn Arg Lys Asp 
Ala 
13 O 
Phe Lieu. Pro Ala 
14 O 
Leul Pro Leul Pro 
135 
Pro Arg Pro Gly 
Ile Lieu Ala 
150 
Pro Pro Pro Glin Pro Wall 
145 
Gly Pro Asp 
155 
Gly 
Ala Met Wall 
1.65 
Pro Leu Gly Pro Ser Glin Gly Arg Ser Pro 
17O 
Ser 
<210s, SEQ ID NO 49 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 49 
Lell 
5 
Asp Ser Ser Pro 
1. 1O 
Lieu. Tyr Thr Asp Asp 
25 
Glu Thir Wall Pro 
45 
Asp Gly Ser 
35 
Gly Gly Ala 
4 O 
Ala Asp Glin 
Glin 
SO 
Ala Wall Ile Glin. I 
6 O 
Lell Lieu. Arg Lieu. Arg Pro 
55 
Gly 
Thir Phe Lieu. Glin Pro 
70 
Arg Ser 
65 
Arg Arg Asp Gly 
Phe Glu Ala Ser Phe 
90 
Ser Lieu. His Asp Pro 
85 
Arg 
Glu Wall Glin Ser Glu Ala His 
105 
Asp Gly Tyr Asn 
1OO 
Pro Pro His 
12 O 
Pro Asn Ser 
115 
His Lieu. Arg Asp 
Ala 
13 O 
Phe Pro 
14 O 
Leul Pro Leul Pro 
135 
Pro Arg Leul Pro Gly 
Ile Ala 
150 
Pro Pro Lell Pro Glin Pro Pro Wall 
145 
Gly Asp 
155 
y 
Ala Met Wall 
1.65 
Pro Leu Gly Pro Ser Glin Gly Ser Pro 
17O 
Arg 
Ser 
What is claimed is: 
1. A polypeptide variant having a sequence selected from 
the group of the sequences in Table 1. 
2. The variant of claim 1, wherein the variant further com 
prises one or more of the following modifications: (a) an 
amino-terminal truncation of no more than 8 amino acid 
residues; and (b) a carboxyl-terminal truncation of no more 
than 12 amino acid residues. 
3. The variant of claim 1, wherein the variant is covalently 
linked to polyethylene glycol (PEG) or polysialic acid. 
4. The variant of claim3, wherein the variant further com 
prises a branched, 40 kDa PEG group, covalently linked to a 
cysteine of the variant. 
11 O 
Pro 
Pro 
Ser 
Ser 
Glu 
Lel 
Lel 
Lel 
Lel 
11 O 
Pro 
Ser 
Ser 
Arg Gly 
Pro Glu 
Ser Asp 
160 
Tyr Ala 
17s 
Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
15 
Ala Cys Glin Thr Glu Ala His Lieu. Glu Ile Arg 
Ser Luell 
Gly Val 
Gly 
8O 
Lieu. Luell 
95 
Pro Leu 
Arg Gly 
Pro Glu 
Ser Asp 
160 
Tyr Ala 
17s 
5. The variant of claim 1, wherein the variant is fused to a 
heterologous amino acid sequence consisting of one of the 
following: an IgG constant domain or fragment thereof. 
Human Serum Albumin (HSA); and albumin-binding 
polypeptides. 
6. The variant of claim 5, wherein the heterologous amino 
acid sequence is fused to the amino-terminal of the variant. 
7. The variant of claim 5, wherein the heterologous amino 
acid sequence is fused to the carboxy-terminal of the variant. 
8. A multimer consisting of at least one of the variants of 
claim 1. 
9. The multimer of claim 8, wherein the multimer is a 
homodimer. 
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10. A polypeptide or protein variant, comprising Variant 76 
(V76). 
11. The variant of claim 10, wherein the variant with 
PEGylation at the cysteine residue at position 154. 
12. The variant of claim 11, wherein the variant further 
comprises a branched, 40 kDa PEG group at position 154. 
13. A pharmaceutical composition comprising a variant 
selected from the group consisting of the sequences in Table 
1. 
14. The pharmaceutical composition of claim 13, further 
comprising Variant 76 (V76), with PEGylation at the cysteine 
residue at position 154. 
15. A method for treating a patient comprising administer 
ing to said patient a therapeutically effective amount of a 
Fibroblast Growth Factor 21 (FGF21) polypeptide or protein 
variant, wherein said patient exhibits one or more of FGF21 
associated disorders 
16. The method of claim 15, wherein the FGF21-associ 
ated disorders consist of one or more of the following: obe 
sity, type 1 and type 2 diabetes mellitus, pancreatitis, dyslipi 
demia, nonalcoholic steatohepatitis (NASH), insulin 
resistance, hyperinsulinemia, glucose intolerance, hypergly 
cemia, metabolic syndrome, and other metabolic disorders 
17. The method of claim 16, wherein the FGF21-associ 
ated disorder consists of type 1 diabetes mellitus. 
18. The method of claim 16, wherein the FGF21-associ 
ated disorder consists of type 2 diabetes mellitus. 
19. A method for treating a patient comprising administer 
ing to said patient a pharmaceutical composition comprising 
a therapeutically effective amount of a Fibroblast Growth 
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Factor 21 (FGF21) polypeptide or protein variant, wherein 
said patient exhibits one or more of FGF21-associated disor 
ders. 
20. A method for treating a patient comprising administer 
ing to said patient a therapeutically effective amount of a 
Fibroblast Growth Factor 21 (FGF21) polypeptide or protein 
variant, wherein said patient exhibits one or more of FGF21 
associated disorders, wherein said variant further comprises 
Variant 76 (V76), with PEGylation at the cysteine residue at 
position 154. 
21. The method of claim 20, wherein the FGF21-associ 
ated disorders consist of one or more of the following: obe 
sity, type 1 and type 2 diabetes mellitus, pancreatitis, dyslipi 
demia, nonalcoholic steatohepatitis (NASH), insulin 
resistance, hyperinsulinemia, glucose intolerance, hypergly 
cemia, metabolic syndrome, and other metabolic disorders 
22. The method of claim 21, wherein the FGF21-associ 
ated disorder consists of type 1 diabetes mellitus. 
23. The method of claim 21, wherein the FGF21-associ 
ated disorder consists of type 2 diabetes mellitus. 
24. A method for reducing one or more of hyperglycemia, 
hyperinsulinemia, liver lipids, and weight gain in a patient in 
need, comprising administering to said patient a therapeuti 
cally effective amount of a Fibroblast Growth Factor 21 
(FGF21) polypeptide or protein variant. 
25. The method of claim 24, wherein the variant further 
comprises Variant 76 (V76), with PEGylation at the cysteine 
residue at position 154. 
c c c c c 
